KR20150064521A - Fermented composition comprising bamboo salt and rhynchosia nulubilis - Google Patents
Fermented composition comprising bamboo salt and rhynchosia nulubilis Download PDFInfo
- Publication number
- KR20150064521A KR20150064521A KR1020130149336A KR20130149336A KR20150064521A KR 20150064521 A KR20150064521 A KR 20150064521A KR 1020130149336 A KR1020130149336 A KR 1020130149336A KR 20130149336 A KR20130149336 A KR 20130149336A KR 20150064521 A KR20150064521 A KR 20150064521A
- Authority
- KR
- South Korea
- Prior art keywords
- fermented
- bamboo salt
- composition
- fermentation
- sample
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 154
- 241001330002 Bambuseae Species 0.000 title claims abstract description 103
- 235000017166 Bambusa arundinacea Nutrition 0.000 title claims abstract description 101
- 235000017491 Bambusa tulda Nutrition 0.000 title claims abstract description 101
- 235000015334 Phyllostachys viridis Nutrition 0.000 title claims abstract description 101
- 239000011425 bamboo Substances 0.000 title claims abstract description 101
- 150000003839 salts Chemical class 0.000 title claims abstract description 100
- 240000008301 Rhynchosia minima Species 0.000 title claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000011593 sulfur Substances 0.000 claims abstract description 44
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 44
- 241000272525 Anas platyrhynchos Species 0.000 claims abstract description 32
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 235000013402 health food Nutrition 0.000 claims abstract description 17
- 206010019133 Hangover Diseases 0.000 claims abstract description 13
- 238000000855 fermentation Methods 0.000 claims description 57
- 230000004151 fermentation Effects 0.000 claims description 57
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 48
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 235000016870 Allium oleraceum Nutrition 0.000 claims description 31
- 235000011403 Allium vineale Nutrition 0.000 claims description 31
- 244000109568 Allium vineale Species 0.000 claims description 30
- 244000068988 Glycine max Species 0.000 claims description 23
- 235000010469 Glycine max Nutrition 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 230000032683 aging Effects 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 239000010903 husk Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 241000272517 Anseriformes Species 0.000 claims 1
- 230000001055 chewing effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 230000005778 DNA damage Effects 0.000 abstract description 13
- 231100000277 DNA damage Toxicity 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 8
- 238000011084 recovery Methods 0.000 abstract description 5
- 240000002234 Allium sativum Species 0.000 abstract description 4
- 235000004611 garlic Nutrition 0.000 abstract description 4
- 230000001953 sensory effect Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 241000913743 Rhynchosia Species 0.000 abstract 3
- 230000035764 nutrition Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- 206010016256 fatigue Diseases 0.000 description 37
- 238000004458 analytical method Methods 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 241000287828 Gallus gallus Species 0.000 description 18
- 235000013305 food Nutrition 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000003078 antioxidant effect Effects 0.000 description 14
- 239000013642 negative control Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 240000007594 Oryza sativa Species 0.000 description 11
- 235000007164 Oryza sativa Nutrition 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 235000009566 rice Nutrition 0.000 description 11
- 239000012085 test solution Substances 0.000 description 11
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 241000272522 Anas Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 235000013527 bean curd Nutrition 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000012086 standard solution Substances 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 235000019784 crude fat Nutrition 0.000 description 8
- 235000018823 dietary intake Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 238000012453 sprague-dawley rat model Methods 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000017060 Arachis glabrata Nutrition 0.000 description 6
- 244000105624 Arachis hypogaea Species 0.000 description 6
- 235000010777 Arachis hypogaea Nutrition 0.000 description 6
- 235000018262 Arachis monticola Nutrition 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 6
- -1 ethyl oleate Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 235000020232 peanut Nutrition 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 5
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 238000010422 painting Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 229940071117 starch glycolate Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 3
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- HTBIAUMDQYXOFG-UHFFFAOYSA-N 3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pentanoic acid Chemical compound CCC(C)C(C(O)=O)N(C)C(=O)OC(C)(C)C HTBIAUMDQYXOFG-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- RSYUFYQTACJFML-DZGCQCFKSA-N afzelechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-DZGCQCFKSA-N 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229940060799 clarus Drugs 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 238000003927 comet assay Methods 0.000 description 2
- 231100000170 comet assay Toxicity 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 229940116318 copper carbonate Drugs 0.000 description 2
- 229910000009 copper(II) carbonate Inorganic materials 0.000 description 2
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 2
- 239000011646 cupric carbonate Substances 0.000 description 2
- 235000019854 cupric carbonate Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 229940068840 d-biotin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229960002413 ferric citrate Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000013882 gravy Nutrition 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229960004051 menadione sodium bisulfite Drugs 0.000 description 2
- XDPFHGWVCTXHDX-UHFFFAOYSA-M menadione sodium sulfonate Chemical compound [Na+].C1=CC=C2C(=O)C(C)(S([O-])(=O)=O)CC(=O)C2=C1 XDPFHGWVCTXHDX-UHFFFAOYSA-M 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 2
- 239000001230 potassium iodate Substances 0.000 description 2
- 235000006666 potassium iodate Nutrition 0.000 description 2
- 229940093930 potassium iodate Drugs 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019643 salty taste Nutrition 0.000 description 2
- 235000021003 saturated fats Nutrition 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 239000011667 zinc carbonate Substances 0.000 description 2
- 235000004416 zinc carbonate Nutrition 0.000 description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 description 2
- XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 description 1
- AUMLONZWTOQAIR-UHFFFAOYSA-N 2-tert-butylbenzene-1,4-diol Chemical compound C(C)(C)(C)C1=C(O)C=CC(=C1)O.C(C)(C)(C)C1=C(O)C=CC(=C1)O AUMLONZWTOQAIR-UHFFFAOYSA-N 0.000 description 1
- XIIAYQZJNBULGD-XWLABEFZSA-N 5α-cholestane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 XIIAYQZJNBULGD-XWLABEFZSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 241001313207 Gonepteryx rhamni Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 108010029165 Metmyoglobin Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000002245 Penicillium camembertii Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 244000233217 Tulbaghia alliacea Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- XIIAYQZJNBULGD-LDHZKLTISA-N cholestane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XIIAYQZJNBULGD-LDHZKLTISA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 108010044238 ferrylmyoglobin Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- ZGNITFSDLCMLGI-UHFFFAOYSA-N flubendiamide Chemical compound CC1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(I)=C1C(=O)NC(C)(C)CS(C)(=O)=O ZGNITFSDLCMLGI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- JBXYCUKPDAAYAS-UHFFFAOYSA-N methanol;trifluoroborane Chemical compound OC.FB(F)F JBXYCUKPDAAYAS-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- YLLIGHVCTUPGEH-UHFFFAOYSA-M potassium;ethanol;hydroxide Chemical compound [OH-].[K+].CCO YLLIGHVCTUPGEH-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 죽염 및 쥐눈이콩을 발효하여 제조된 발효조성물, 이의 제조방법, 및 상기 발효조성물의 약제 또는 건강식품으로의 용도에 관한 것이다.The present invention relates to a fermentation composition prepared by fermenting bamboo salt and rice husk, a method for producing the fermented composition, and a use of the fermented composition as a medicine or a health food.
'죽염'은 우리나라 천일염을 지리산 왕대나무에 다져 넣고 소나무 장작으로 태우는 공정을 8번 반복하고 9번째는 송진으로 1,000℃ 이상의 고열로 녹여 내린 물질이다. 'Bamboo salt' is a process in which Korean sunbeams are poured into bamboo trees of Jiri Mountain and burned with pine wood, and the ninth is the material melted with high heat of 1,000 ℃ or higher by the rosin.
죽염은 간수를 뺀 천일염을 왕대나무 마디 속에 다져 넣고 위를 황토로 막은 후 800℃ 가량의 소나무 장작불로 구워낸 후 재로 변한 대나무와 황토덩이를 걷어내고 소금 기둥이 되어 버린 구운 소금을 취하여 분쇄하고 다시 대나무에 채우는 동일과정을 8회 반복한 후 9회째는 8회 구운 소금을 가열 용융시키되 액화한 송진을 연료로 공기를 송풍하면서 1000℃ 이상의 온도로 가열함으로써 소금괴가 용융되어 액체로 흘러내리게 하여 Ash와 Silicate을 제거함으로써 제조될 수 있다.Bamboo salt is made by bamboo shoots that have been cut into ash pellets, crushed into bamboo shoots, and then crushed into bamboo shoots. And then heated to a temperature of 1000 ° C or higher while air is blown through the liquefied rosin as fuel to melt the salt and flow down into the liquid, And removing the silicate.
죽염은 대나무에 채워 굽고 분쇄하는 횟수 및 굽는 온도에 따라 일반적으로 3회, 9회 죽염, 단염 및 자죽염 등으로 나눌 수 있다. 현재 시중에는 여러 종류의 죽염이 시판되고 있으며, 죽염에 대한 순도, 미네랄 조성, 구조 분석 및 죽염의 약리 효과 등 기능특성을 구명한 연구들이 점차적으로 발표되고 있다. Bamboo salt can be divided into bamboo, bamboo, bamboo, bamboo, bamboo, and bamboo, depending on the number of times of grilling and grinding and the baking temperature. Several kinds of bamboo salt are commercially available in the market, and studies on the functional characteristics such as purity, mineral composition, structure analysis and pharmacological effect of bamboo salt have been gradually announced.
최근의 건강지향성 식생활 변화 패턴으로 볼 때 식염 농도를 낮추어 섭취하려는 경향이 지배적이고, 식염의 단점을 보완할 수 있는 기능성 소재인 죽염을 첨가한 가공식품들이 시장에 속속 등장하고 있다.Recent trends in health-oriented eating habits have been dominated by lower salt intake and processed foods with bamboo salt, which is a functional material that can compensate for the drawbacks of salt, are emerging in the market.
쥐눈이콩은 서목태(鼠目太)라고 하며 학명으로는 Rhynchosia Nulubilis이다. 콩과의 다년생 만초(蔓草)로 줄기와 잎은 갈색이다. 7월에 노란 꽃이 피어 타원형의 깍지 속에 지름 5 ~ 7 ㎜ 정도의 검고 둥근 열매가 여물면 수확한다. '본초강목'에 의하면 빛이 검으면서 반들반들하고 작은 수콩(雄豆)을 약으로 쓰는 것이 더 좋다고 한다. 유황을 뿌리고 재배하면 약성이 더욱 좋아지는 것으로 알려져 있다. 특히, 성질이 따뜻하고, 맛은 달며, 독이 없다.The bean is called Seomoktae, and its scientific name is Rhynchosia It is Nulubilis . It is a perennial herbaceous plant of beans and its stems and leaves are brown. A yellow flower blooms in July, and a black and round fruit about 5 ~ 7 ㎜ in diameter is harvested in an elliptical pod. According to the 'primordial gangmok', it is better to use a small bean curd (豆 豆) as a medicine while the light is black. Sulfur spraying and growing are known to be more beneficial. In particular, the nature is warm, the taste is sweet, and there is no poison.
쥐눈이콩이 뛰어난 약성을 가지는 대표적인 이유는 껍질에 함유된 검은색을 띄는 색소에 있는 것으로 알려져 있다. 이 약성은 안토시아닌으로 인한 활성산소의 독성이 활성화되는 것을 억제하는 항산화 작용과 시력 향상 효과, 콜라겐 기능 향상으로 인한 피부미용에 특히 뛰어나다. 또한 혈액순환을 촉진하고, 이뇨작용을 도와 부종기를 낮추며, 강한 해독작용을 가진다. 그러나 이러한 콩의 탁월한 장점에도 불구하고 쥐눈이콩은 정월 음식에만 먹는다는 속설과 같이 조리해서 먹기에 매우 까다롭고 소화가 어려운 편이다. A typical reason for the superiority of rice husk beans is that they are found in black pigment in the shell. This drug is particularly excellent for antioxidant, vitreous and collagen functions, which inhibit the active oxygen toxicity caused by anthocyanin. It also promotes blood circulation, helps diuretic action, lowers edema, and has a strong detoxifying action. However, in spite of the excellent merits of these beans, it is very difficult to digest and difficult to eat because the cooked bean is cooked just like the New Year 's meal.
본 발명자들은 죽염의 우수성을 알리고 지역발전을 도모하고자 기호성 및 기능성 효과뿐만 아니라 안전성이 보장된 죽염 및 죽염을 이용한 제품 개발을 위해 예의노력한 결과, 죽염 및 쥐눈이콩을 발효하여 제조된 발효조성물이 총 페놀 함량 및 항산화 활성이 우수하고, DNA 손상 보호 활성을 가지며, 피로회복 효과 및 숙취해소 효과를 가지는 것을 확인함으로써 약제 또는 건강식품으로 유용하게 사용될 수 있음을 밝힘으로써 본 발명을 완성하였다.The present inventors have made intensive efforts to develop products using bamboo salt and bamboo salt that are safe as well as palatability and functional effects in order to promote the excellence of bamboo salt and to promote local development. As a result, the fermented composition prepared by fermenting bamboo salt and rice bran And has antioxidant activity, DNA damage-protecting activity, fatigue recovery effect and hangover resolution effect, and thus, the present invention has been completed.
본 발명의 목적은 쥐눈이콩(Rhynchosia Nulubilis), 죽염, 유근피, 밭마늘 및 유황오리를 발효시켜 제조한 발효조성물을 제공하는 것이다.The object of the present invention is to provide a method for the production of Rhynchosia Nulubilis ), bamboo salt, yugunipi , field garlic, and sulfur duck.
본 발명의 또다른 목적은 상기 발효조성물을 제조하는 방법을 제공하는 것이다.It is still another object of the present invention to provide a method for producing the above fermented composition.
본 발명의 다른 목적은 상기 발효조성물을 이용한 약제 또는 건강식품을 제공하는 것이다.It is another object of the present invention to provide a pharmaceutical or health food using the above fermented composition.
상기 목적을 달성하기 위하여, 본 발명은 쥐눈이콩(Rhynchosia Nulubilis), 죽염, 유근피, 밭마늘 및 유황오리를 포함하는 발효조성물을 제공한다.In order to achieve the above object, the present invention jwinunyi bean (Rhynchosia Nulubilis ), bamboo salt, rhizome , field garlic and sulfur duck.
또한, 본 발명은 In addition,
1) 쥐눈이콩을 세척 및 증자 후 식히는 단계;1) washing and growing the bean sole and cooling;
2) 상기 단계 1)의 쥐눈이콩에 누룩을 접종한 후 발효시킨 다음 건조시키는 단계;2) Inoculating the yeast into the legs of the step 1), then fermenting the yeast, and then drying it;
3) 상기 단계 2)의 건조된 쥐눈이콩에 죽염, 유근피, 밭마늘 및 유황오리를 혼합시키는 단계;3) mixing the bamboo shoots, yucci, field garlic, and sulfur ducks with dried legs of step 2);
4) 상기 단계 3)의 혼합물을 1차 숙성시킨 후 여과한 다음 가열하는 단계;4) first aging the mixture of step 3), filtering and then heating;
5) 상기 단계 4)의 발효물을 2차 숙성시키는 단계를 포함하는,5) secondary aging the fermented product of step 4)
쥐눈이콩, 죽염, 유근피, 밭마늘 및 유황오리를 포함하는 발효조성물의 제조방법을 제공한다.The present invention also provides a method for producing a fermentation composition comprising a bean curd, a bamboo salt, a rhizome, a field garlic, and a sulfur duck.
또한, 본 발명은 상기 발효조성물을 함유하는 피로회복용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition containing a fermented composition containing the above fermented composition.
또한, 본 발명은 상기 발효조성물을 함유하는 숙취해소용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for hangover breakage containing the above fermented composition.
또한, 본 발명은 상기 발효조성물을 함유하는 피로회복용 건강식품을 제공한다.In addition, the present invention provides a health food containing a fermented composition containing the fermented composition.
아울러, 본 발명은 상기 발효조성물을 함유하는 숙취해소용 건강식품을 제공한다.In addition, the present invention provides a health food for hangover marrow containing the above fermented composition.
본 발명의 죽염 및 쥐눈이콩을 발효하여 생산된 발효조성물은 시험관내(In vitro) 실험에서 총 페놀 함량이 우수하고, 우수한 항산화 활성을 가지며, DNA 손상 보호 활성을 가지는 것을 확인하였으며, 생체 내(In vivo) 실험으로 운동으로 유발된 피로 모델 동물 및 알코올 투여로 유발된 숙취 모델 동물에서 각각 항산화 활성 및 DNA 손상 보호 활성을 가지는 것을 확인함으로써, 상기 발효조성물을 숙취해소 및 피로회복을 위한 약제 또는 건강식품, 특히 기능성 발효음료 개발에 유용하게 사용될 수 있음을 알 수 있다.Fermented compositions produced by fermenting the bamboo salt and jwinunyi beans of the present invention was confirmed to have an in vitro (In vitro) test has a total phenolic content excellent in, and have excellent antioxidant activity, DNA damage protection activity, in vivo (In vivo experiment showed that the fatigue model animal induced by exercise and the hangover model animal induced by alcohol administration had antioxidative activity and DNA damage protective activity, respectively. Thus, the fermentation composition can be used as a medicine or health food for relieving hangover and restoring fatigue , And particularly useful for the development of functional fermented beverages.
도 1은 죽염과 쥐눈이콩 발효에 의해 생성된 발효조성물의 제조과정을 보여주는 그림이다.
도 2는 쥐눈이콩의 성분 분석표를 보여주는 그림이다.
도 3은 발효건조콩의 성분 분석표를 보여주는 그림이다.
도 4는 발효조성물의 성분 분석표를 보여주는 그림이다.
도 5는 발효조성물(숙성)의 성분 분석표를 보여주는 그림이다.
도 6은 죽염과 쥐눈이콩 발효에 의해 생성된 발효조성물의 총 페놀 함량을 보여주는 그래프이다:
모든 수치는 평균 ± 표준편차임;
a-c, P<0.05에서 유의적 차이는 ANOVA에 의해 나타냄;
(A) 발효된 쥐눈이콩;
(B) 발효된 쥐눈이콩 + 천일염;
(C) 발효된 쥐눈이콩 + 죽염; 및
(D) 발효된 쥐눈이콩 + 죽염 + 유근피 + 밭마늘 + 유황오리.
도 7은 죽염과 쥐눈이콩 발효에 의해 생성된 발효조성물의 퍼옥시라디칼 소거능을 보여주는 그래프이다:
수치는 평균 ± 표준편차임;
a-d, P<0.05에서 유의적 차이는 던컨의 다중범위검정(Duncan's multiple range test)로 나타냄;
(A) 발효된 쥐눈이콩;
(B) 발효된 쥐눈이콩 + 천일염;
(C) 발효된 쥐눈이콩 + 죽염; 및
(D) 발효된 쥐눈이콩 + 죽염 + 유근피 + 밭마늘 + 유황오리.
도 8은 HepG2 세포 모델에서 AAPH로 유도된 산화적 스트레스에 대한 죽염과 쥐눈이콩 발효에 의해 생성된 발효조성물의 세포적 항산화 능력을 보여주는 그래프이다:
대조군: HBSS 처리된 음성대조군;
AAPH: 80 μM AAPH 처리된 양성대조군;
수치는 평균 ± 표준편차임;
a-d, P<0.05에서 유의적 차이는 던컨의 다중범위검정(Duncan's multiple range test)로 나타냄;
(A) 발효된 쥐눈이콩;
(B) 발효된 쥐눈이콩 + 천일염;
(C) 발효된 쥐눈이콩 + 죽염; 및
(D) 발효된 쥐눈이콩 + 죽염 + 유근피 + 밭마늘 + 유황오리.
도 9는 인간 백혈구에서 200 μM H2O2로 유도된 DNA 손상에 대한 죽염과 쥐눈이콩 발효에 의해 생성된 발효조성물의 처리 효과를 보여주는 그래프이다:
수치는 평균 ± 표준편차임;
다른 첨자를 갖는 막대는 던컨의 다중범위검정(Duncan's multiple range test)로 나타냄;
NC: 1% DMSO (산화 자극 없음)로 처리된 양성대조군;
(A) 발효된 쥐눈이콩;
(B) 발효된 쥐눈이콩 + 천일염;
(C) 발효된 쥐눈이콩 + 죽염; 및
(D) 발효된 쥐눈이콩 + 죽염 + 유근피 + 밭마늘 + 유황오리.FIG. 1 is a diagram showing a process for producing a fermented composition produced by bamboo salt and bean fermentation. FIG.
Fig. 2 is a diagram showing an ingredient analysis chart of the snow bean bean.
Fig. 3 is a diagram showing an ingredient analysis table of fermented dried beans. Fig.
FIG. 4 is a view showing an ingredient analysis table of the fermentation composition. FIG.
Fig. 5 is a diagram showing an ingredient analysis table of the fermentation composition (aging). Fig.
Figure 6 is a graph showing the total phenolic content of the fermentation composition produced by bamboo salt and bean fermentation:
All figures are mean ± standard deviation;
ac, significant difference at P <0.05 was indicated by ANOVA;
(A) fermented whole bean beans;
(B) Fermented chicken legs + sun salt;
(C) Fermented chicken legs + bamboo salt; And
(D) Fermented chicken legs + bamboo salt + yuu pee + field garlic + sulfur duck.
Figure 7 is a graph showing the peroxy radical scavenging activity of the fermentation composition produced by bamboo salt and bean fermentation:
Values are mean ± standard deviation;
The significant difference at ad, P < 0.05, is indicated by Duncan's multiple range test;
(A) fermented whole bean beans;
(B) Fermented chicken legs + sun salt;
(C) Fermented chicken legs + bamboo salt; And
(D) Fermented chicken legs + bamboo salt + yuu pee + field garlic + sulfur duck.
8 is a graph showing the cellular antioxidant capacity of the fermentation composition produced by bamboo salt and soybean fermentation against oxidative stress induced by AAPH in the HepG2 cell model:
Control group: HBSS-treated negative control;
AAPH: positive control treated with 80 [mu] M AAPH;
Values are mean ± standard deviation;
The significant difference at ad, P < 0.05, is indicated by Duncan's multiple range test;
(A) fermented whole bean beans;
(B) Fermented chicken legs + sun salt;
(C) Fermented chicken legs + bamboo salt; And
(D) Fermented chicken legs + bamboo salt + yuu pee + field garlic + sulfur duck.
9 is a graph showing the effect of treatment of the fermentation composition produced by bamboo salt and soybean fermentation on DNA damage induced in 200 μM H 2 O 2 in human leukocytes:
Values are mean ± standard deviation;
Bars with different subscripts are represented by Duncan's multiple range test;
NC: positive control treated with 1% DMSO (no oxidative stimulation);
(A) fermented whole bean beans;
(B) Fermented chicken legs + sun salt;
(C) Fermented chicken legs + bamboo salt; And
(D) Fermented chicken legs + bamboo salt + yuu pee + field garlic + sulfur duck.
이하, 본 발명에서 사용되는 용어를 정의한다.Hereinafter, terms used in the present invention are defined.
본 발명에서 사용되는 용어 '쥐눈이콩'은 서목태(鼠目太)라고 하며 학명으로는 Rhynchosia Nulubilis이다. 콩과의 다년생 만초(蔓草)로 줄기와 잎은 갈색이다. 7월에 노란 꽃이 피어 타원형의 깍지 속에 지름 5∼7㎜ 정도의 검고 둥근 열매가 여물면 수확한다. '본초강목'에 의하면 빛이 검으면서 반들반들하고 작은 수콩(雄豆)을 약으로 쓰는 것이 더 좋다고 한다. 유황을 뿌리고 재배하면 약성이 더욱 좋아지는 것으로 알려져 있다. 성질이 따뜻하고, 맛은 달며, 독이 없다.That the term "jwinunyi beans" are seomoktae (鼠目太) used in the present invention, and the scientific name is Rhynchosia It is Nulubilis . It is a perennial herbaceous plant of beans and its stems and leaves are brown. A yellow flower blooms in July, and a black round fruit about 5-7 mm in diameter is harvested in an oval-shaped pod. According to the 'primordial gangmok', it is better to use a small bean curd (豆 豆) as a medicine while the light is black. Sulfur spraying and growing are known to be more beneficial. The nature is warm, the taste is sweet, and there is no poison.
본 발명에서 사용되는 용어 '죽염'은 우리나라 천일염을 지리산 왕대나무에 다져 넣고 소나무 장작으로 태우는 공정을 8번 반복하고 9번째는 송진으로 1,400℃ 안팎의 고열로 녹여 내린 물질이다.The term "bamboo salt" used in the present invention refers to a substance which is made by bamboo bark of Jiri Mountain and burned with pine wood in 8 times, and 9th is melted with high heat of around 1,400 ℃ by rosin.
본 발명에서 사용되는 용어 '유황오리'는 오리에게 유황을 먹여, 유황독을 오리로 법제한 것으로서, 오리 체내에 들어간 유황은 독성이 제거되고 강한 약성이 축적되어 있다.The term " sulfur duck " used in the present invention means sulfur fed to ducks, sulfur ducks as ducks, and sulfur contained in ducks is toxic and accumulated strong toxicity.
본 발명에서 사용되는 용어 '밭마늘'은 밭에서 기른 마늘로서, 살균, 살충, 거악생신하는 작용이 뛰어나고, 마늘즙의 찐득찐득한 성분은 뼈를 단단하게 한다. 한편, 논마늘은 논의 축적된 농약독으로 인해 약으로 사용하지 못한다.The term "field garlic" used in the present invention is a garlic raised in a field, which is excellent in sterilization, insecticidal action, gigantic birth, and hard-boiled ingredients of garlic juice make the bones hard. On the other hand, rice paddy can not be used as medicine because of accumulated pesticide poison.
본 발명에서 사용되는 용어 '유근피'는 느릅나무과 느릅나무의 나무껍질 또는 뿌리껍질로서, 효능으로 수술한 상처를 낫게 해주고 비위 질환에 매우 좋으며, 특히 위궤양, 십이지장궤양, 소장, 대장, 직장, 궤양, 식도궤양 등 제반 궤양증에 탁월한 효과를 나타낸다.As used herein, the term " yugunipi " refers to a bark or root bark of elm and elm, which improves wound scarring by virtue of its efficacy and is very good for nasal diseases, and in particular is useful for the treatment of gastric ulcer, duodenal ulcer, small intestine, Esophageal ulcers, and other ulcers.
본 발명에서 사용되는 용어 '숙취'는 술에 몹시 취한 뒤의 수면에서 깬 후에 특이한 불쾌감이나 두통, 또는 심신의 작업능력 감퇴 등이 1 ~ 2일간 지속되는 것을 의미한다.The term " hangover " used in the present invention means that unusual discomfort, headache, or decline in working ability of the body and mind, etc., lasts for 1 to 2 days after being awakened from the surface after drunkenly drinking.
본 발명에서 사용되는 용어 '피로'는 연속 및 반복되는 정신적 또는 육체적 작업에 수반해서 발생하는 심신기능의 저하상태를 의미하며, 피로가 나타나는 방식으로부터 정신피로와 육체피로, 중추피로와 말초피로, 급성피로와 만성피로 등으로 구분되며, 그 외에 기능저하가 심한 기관을 들어 근피로, 신경피로 및 심장피로 등으로 구분된다.
The term " fatigue " as used in the present invention means a depressed state of mental and physical functions caused by continuous and repeated mental or physical work. It is a state in which fatigue manifests itself as mental fatigue and physical fatigue, central fatigue and peripheral fatigue, Fatigue, and chronic fatigue. In addition, there is an orgasm with severe deterioration in function, and it is divided into muscle, nerve fatigue and heart fatigue.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 쥐눈이콩(Rhynchosia Nulubilis), 죽염, 유근피, 밭마늘 및 유황오리를 포함하는 발효조성물을 제공한다.The present invention relates to the use of Rhynchosia Nulubilis ), bamboo salt, rhizome , field garlic and sulfur duck.
상기 발효조성물에 있어서, 쥐눈이콩 : 죽염 : 유근피 : 밭마늘 : 유황오리가 1 : 1 : 0.5 내지 1 : 0.5 내지 1 : 0.5 내지 1의 중량 비율로 포함되는 것이 바람직하고, 1 : 1 : 1 : 0.7 : 0.8의 중량 비율로 포함되는 것이 더욱 바람직하다.In the fermentation composition, it is preferable that the ratio is 1: 1: 1: 1 to 1: 1: 0.5 to 1: 0.5 to 1: 0.5 to 1, and the ratio of beans: bamboo salt: More preferably in a weight ratio of 0.7: 0.8.
상기 쥐눈이콩은 발효시킨 발효콩인 것이 바람직하고, 1) 쥐눈이콩을 세척 및 삶는 단계; 2) 식히는 단계; 3) 누룩을 접종하는 단계; 4) 발효시키는 단계; 및 5) 건조시키는 단계를 포함하는 방법으로 제조된 발효콩인 것이 더욱 바람직하다.Preferably, the above-mentioned chicken legs are fermented fermented soybeans, and 1) washing and boiling the soybeans with the chicken legs; 2) cooling; 3) inoculating the yeast; 4) fermenting step; And 5) drying the fermented soybeans.
상기 죽염은 9회 법제한 자죽염인 것이 바람직하나 이에 한정되지 않고 모든 죽염은 모두 사용가능하다. It is preferable that the bamboo salt is a bamboo salt of bamboo which is used for 9 times, but not limited thereto, all bamboo salts can be used.
상기 죽염은 1) 천일염을 대나무통에 넣고 황토로 입구를 막는 단계; 2) 죽염로에 대나무를 담고 소나무 장작으로 가열(800℃)하는 단계; 3) 죽염로를 식힌 후 선별하는 단계; 4) 구운 소금을 분쇄한 후 다시 1) ~ 3) 단계를 8회 반복하는 단계; 5) 9회 구운 소금을 가열(1400℃)하여 소금괴가 용융되어 액체로 흘러내리게 하여 Ash 및 silicate를 제거하는 단계를 포함하는 제조방법으로 제조된 것을 사용하는 것이 더욱 바람직하다.
The bamboo salt is formed by 1) placing the sun salt in a bamboo container and blocking the inlet with yellow soil; 2) Bamboo bamboo in bamboo shoots and heating (800 ℃) with pine wood; 3) a step of cooling and bifurcating the bamboo salt; 4) pulverizing the baked salt and repeating steps 1) to 3) 8 times; 5) It is more preferable to use a product made by a manufacturing method comprising heating the salt baked 9 times (1400 ° C) so that the salt is melted and flowed down into the liquid to remove the ash and the silicate.
또한, 본 발명은 In addition,
1) 쥐눈이콩을 세척 및 증자 후 식히는 단계;1) washing and growing the bean sole and cooling;
2) 상기 단계 1)의 쥐눈이콩에 누룩을 접종한 후 발효시킨 다음 건조시키는 단계;2) Inoculating the yeast into the legs of the step 1), then fermenting the yeast, and then drying it;
3) 상기 단계 2)의 건조된 쥐눈이콩에 죽염, 유근피, 밭마늘 및 유황오리를 혼합시키는 단계;3) mixing the bamboo shoots, yucci, field garlic, and sulfur ducks with dried legs of step 2);
4) 상기 단계 3)의 혼합물을 1차 숙성시킨 후 여과한 다음 가열하는 단계;4) first aging the mixture of step 3), filtering and then heating;
5) 상기 단계 4)의 발효물을 2차 숙성시키는 단계를 포함하는,5) secondary aging the fermented product of step 4)
쥐눈이콩, 죽염, 유근피, 밭마늘 및 유황오리를 포함하는 발효조성물의 제조방법을 제공한다.The present invention also provides a method for producing a fermentation composition comprising a bean curd, a bamboo salt, a rhizome, a field garlic, and a sulfur duck.
상기 제조 방법에 있어서, 단계 1)의 증자는 쥐눈이콩을 실온에서 10시간 내지 15시간 침지ㅏ여 센불에서 3시간, 약한 불에서 3시간 동안 증자시키는 것이 바람직하다.In the above method, in step 1), the soybean is preferably dipped for 10 hours to 15 hours at room temperature, and then heated for 3 hours in a high temperature and for 3 hours in a low temperature.
상기 제조 방법에 있어서, 단계 2)의 발효는 32 내지 40℃에서 15 내지 20시간 동안 발효시키는 것이 바람직하고, 36 내지 38℃에서 18시간 동안 발효시키는 것이 더욱 바람직하다.In the above production method, the fermentation in step 2) is preferably fermented at 32 to 40 DEG C for 15 to 20 hours, more preferably at 36 to 38 DEG C for 18 hours.
상기 제조 방법에 있어서, 단계 2)의 건조는 자연건조법 또는 건조기를 사용하여 건조할 수 있으며, 건조 조건으로는 30 내지 40℃에서 10 내지 20시간인 것이 바람직하고, 35℃에서 12시간 내지 15시간인 것이 더욱 바람직하다.The drying in step 2) may be carried out using a natural drying method or a drying machine. The drying conditions are preferably 30 to 40 ° C for 10 to 20 hours, and 35 ° C for 12 to 15 hours Is more preferable.
상기 제조 방법에 있어서, 단계 3)의 유근피, 밭마늘 및 유황오리는 혼합 전에 전처리하는 것이 바람직하며, 전처리로는 각각 24시간 동안 정제수에 달인 후 열수 추출하는 것이 바람직하다.In the above production method, it is preferable to pre-treat the roots, field garlic and sulfur ducks of the step 3) before mixing, and it is preferable that the pretreatment rods are subjected to hot water extraction after being subjected to purified water for 24 hours each.
상기 제조 방법에 있어서, 단계 3)의 혼합은 쥐눈이콩 : 죽염 : 유근피 : 밭마늘 : 유황오리가 1 : 1 : 0.5 내지 1 : 0.5 내지 1 : 0.5 내지 1의 중량 비율로 혼합되는 것이 바람직하고, 1 : 1 : 1 : 0.7 : 0.8의 중량 비율로 혼합되는 것이 더욱 바람직하다.In the above production method, the mixing of step 3) is preferably carried out at a weight ratio of 1: 1: 0.5 to 1: 0.5 to 1: 0.5 to 1 in the ratio of soybean: bamboo salt: yuukee: field garlic: More preferably in a weight ratio of 1: 1: 1: 0.7: 0.8.
상기 제조 방법에 있어서, 단계 4)의 가열은 숙성된 발효조성물의 미생물 등에 의한 오염을 방지하기 위한 열처리 공정으로서 80 내지 100℃에서 30분 내지 1시간 동안 가열하는 것이 바람직하고, 80 내지 98℃에서 30분 내지 40분간 가열하는 것이 더욱 바람직하다.
In the above production method, the heating in step 4) is preferably a heat treatment step for preventing contamination of the aged fermented composition with microorganisms and the like, preferably at 80 to 100 캜 for 30 minutes to 1 hour, It is more preferable to heat for 30 minutes to 40 minutes.
또한, 본 발명은 본 발명에 따른 발효조성물을 함유하는 피로회복용 약학적 조성물을 제공한다.The present invention also provides a pharmaceutical composition containing a fermented composition according to the present invention.
또한, 본 발명은 본 발명에 따른 발효조성물을 함유하는 숙취해소용 약학적 조성물을 제공한다.The present invention also provides a pharmaceutical composition for hangover use containing the fermentation composition according to the present invention.
본 발명의 약학적 조성물은 본 발명에 따른 발효조성물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. The pharmaceutical composition of the present invention may contain, in addition to the fermentation composition according to the present invention, one or more active ingredients exhibiting the same or similar functions.
본 발명의 약학적 조성물은 약제학적으로 허용 가능한 첨가제를 더 포함할 수 있으며, 이때 약제학적으로 허용 가능한 첨가제로는 전분, 젤라틴화 전분, 미결정셀룰로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니톨, 엿, 아라비아고무, 전호화전분, 옥수수전분, 분말셀룰로오스, 히드록시프로필셀룰로오스, 오파드라이, 전분글리콜산나트륨, 카르나우바 납, 합성규산알루미늄, 스테아린산, 스테아린산마그네슘, 스테아린산알루미늄, 스테아린산칼슘, 백당, 덱스트로스, 소르비톨 및 탈크 등이 사용될 수 있다. 본 발명에 따른 약제학적으로 허용 가능한 첨가제는 상기 조성물에 대해 0.1 ~ 90 중량부 포함되는 것이 바람직하나 이에 한정되는 것은 아니다.The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate Starch glycolate, starch glycolate, starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, sodium carboxymethylcellulose, sodium carboxymethylcellulose, sodium carboxymethylcellulose, Calcium stearate, white sugar, dextrose, sorbitol and talc may be used. The pharmaceutically acceptable additives according to the present invention are preferably included in the composition in an amount of 0.1 to 90 parts by weight, but are not limited thereto.
본 발명의 약학적 조성물은 실제 임상 투여 시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(Calcium carbonate), 수크로스(Sucrose), 락토오스(Lactose) 또는 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제 및 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함될 수 있다. 비수성용제, 현탁용제로는 프로필렌글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The pharmaceutical composition of the present invention may be administered orally or parenterally in various formulations at the time of actual clinical administration. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, . ≪ / RTI > Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose (Lactose), gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used . Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 약학적 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구 투여할 수 있으며, 비경구 투여시 피부 외용 또는 복강내주사, 직장내주사, 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택하는 것이 바람직하다. 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하다.The pharmaceutical composition of the present invention may be administered orally or parenterally in accordance with the desired method, and may be administered orally, parenterally or intraperitoneally, rectally, subcutaneously, intravenously, intramuscularly, It is preferable to select the injection method. The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity.
본 발명의 약학적 조성물의 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도에 따라 그 범위가 다양하며, 일일 투여량은 조성물의 양을 기준으로 0.001 내지 1000 mg/kg이고, 바람직하게는 0.01 내지 100 mg/kg이며, 하루 1 ~ 6 회 투여될 수 있다.The dosage of the pharmaceutical composition of the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of the disease, 0.001 to 1000 mg / kg, preferably 0.01 to 100 mg / kg, and can be administered 1 to 6 times a day.
본 발명의 약학적 조성물은 피로 또는 숙취에 대한 개선 및 치료를 위하여 단독으로, 또는 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.
The pharmaceutical composition of the present invention can be used alone for improvement and treatment of fatigue or hangover, or in combination with methods using hormone therapy, chemotherapy and biological response modifiers.
또한, 본 발명은 본 발명에 따른 발효조성물을 함유하는 피로회복용 건강식품을 제공한다.In addition, the present invention provides a health food containing the fermented composition according to the present invention.
아울러, 본 발명은 본 발명에 따른 발효조성물을 함유하는 숙취해소용 건강식품을 제공한다.In addition, the present invention provides a health food for hangover poultry containing the fermented composition according to the present invention.
본 발명의 건강식품은 본 발명에 따른 발효조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The health food of the present invention can be used as it is or in combination with other food or food ingredients according to the present invention, and can be suitably used according to conventional methods.
본 발명의 건강식품은 건강기능식품 및 건강보조식품을 모두 포함하며, 이들 건강식품의 종류에는 특별한 제한은 없다. 상기 조성물을 첨가할 수 있는 식품의 예로는 음료수, 차, 드링크제, 알코올음료, 비타민 복합제 및 각종 스프류, 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 면류, 껌류, 아이스크림류를 포함한 낙농제품 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.The health food of the present invention includes both health functional food and health supplement food, and there is no particular limitation on the kind of these health food. Examples of the foods to which the composition can be added include dairy products including beverages, tea, drinks, alcoholic beverages, vitamin complexes and various kinds of spices, meat, sausages, bread, chocolates, candies, snacks, confectioneries, noodles, gums, Products, etc., and includes all the health foods in the ordinary sense.
본 발명의 건강식품 중에서 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml당 일반적으로 약 0.01 내지 0.10 g 포함하는 것이 일반적이다. Among the health foods of the present invention, the health beverage composition may contain various flavors or natural carbohydrates as additional components such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.10 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 건강식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명에 따른 발효조성물 100 중량부 당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the fermentation composition according to the present invention.
이하에서는 본 발명의 실시예 및 제조예를 통해 본 발명을 더욱 상세히 설명한다. Hereinafter, the present invention will be described in more detail with reference to Examples and Preparation Examples.
다만, 하기 실시예 및 제조예는 본 발명에 대한 이해를 돕기 위한 것일 뿐, 본 발명의 범위가 하기 실시예 및 제조예로만 제한되는 것은 아니다.
However, the following examples and preparative examples are provided only for the understanding of the present invention, and the scope of the present invention is not limited to the following examples and preparative examples.
<< 실시예Example 1> 죽염과 1> Bamboo salt 쥐눈이콩A little bean 발효에 의해 생성된 발효조성물의 제조 Preparation of fermentation composition produced by fermentation
<1-1> 원료의 선별 및 보관<1-1> Screening and storage of raw materials
제조에 필요한 각 원료별 선별기준은 아래와 같이 설정하였다.Selection criteria for each raw material required for manufacturing are set as follows.
죽염은 9회 자죽염(인산죽염촌(주), 한국)으로서 투명도가 높으며 비교적 균일한 크기로 돌처럼 단단한 것, 짠맛이 강하며 단맛이 나는 것으로 사용하였다.Bamboo salt is a 9-fold bamboo salt (Phosphate Bamboo Salt Village, Korea). It has high transparency, relatively uniform size, hard stone, strong salty taste and sweet taste.
쥐눈이콩은 국산만을 사용하며, 콩알이 깨짐없이 둥근 것, 3 ~ 5 mm로 크기가 고른 것, 검은색을 띠며 윤택이 나는 것과 해충에 의한 이상이 없고 깨끗한 것으로만 사용하였다.The husked beans were only used domestically, and the beans were rounded without any cracks, 3 to 5 mm in size, black, moist and pest-free and clean.
유근피는 국산만을 사용하며, 잘 건조되고 곰팡이가 피지않게 깨끗한 것을 사용하였다. 유근피의 특유의 향이 진하게 나며, 물에 넣었을 때 진행이 많이 나는 것으로 사용하였다.Ukeunpi was only used domestic, well dried and clean to avoid mold. The distinctive scent of yugun pei was bloomed deeply and used as a lot of progress in water.
밭마늘은 국산만을 사용하며, 전체적으로 붉은 빛이 도는 것, 한통 작은 것 4 cm, 큰 것 6 cm로 통통한 것, 껍질이 얇고 잘 건조되어 있는 것과 육쪽마늘인 것을 사용하였다.The field garlic uses only domestically produced whole red light, one small one 4 cm, the
유황오리는 천연유황을 먹여 2년 이상 사육된 것으로 오리고기 특유의 비린 냄새가 없으며, 색은 선홍색에 가깝고 탄력이 있으며 하기의 사육지침서에 따라 육성된 오리만을 사용하였다. Sulfur ducks were fed with natural sulfur for more than 2 years. There was no smell of peculiar birds. Only ducks were used.
상기 유황오리의 사육 지침서는 다음과 같다. The guideline for raising the sulfur duck is as follows.
색이 옅은 노란색을 띠는 고운가루 입자를 띠는 유황Natural sulfur imported from the Indonesian volcanic area,
Sulfur with fine powder particles with a pale yellow color
유황섭취량 : 평균 10 g/dayFeed per duck:
Sulfur Intake: Average 10 g / day
깨끗이 손질되어 잔털 無With built-in hair,
Clean and clean
<1-2> <1-2> 쥐눈이콩의Twigs of beans 발효공정 Fermentation process
우선, 국산 쥐눈이콩을 선별기준에 따라 선별하였다. 선별된 쥐눈이콩을 실온에서 10 ~ 15시간 침지하여 센불에서 3시간, 약한 불에서 3시간 증자하였다. 증자 후에 쥐눈이콩에 누룩을 접종하였다. 누룩 접종시의 콩의 적정한 온도는 누룩활성의 최적온도가 35 ~ 38℃이기 때문에 증자한 콩을 38℃±2로 맞춰서 누룩을 접종하였다. 누룩을 접종한 쥐눈이콩을 18시간 동안 32 ~ 38℃에서 발효시켰다. 최적 발효된 쥐눈이콩의 성상으로는 쥐눈이콩 사이에 끈끈한 점질의 실들이 늘어지는 것, 발효된 콩의 냄새가 구수하게 나는 것, 쉰 냄새가 나지 않는 것, 및 하얗게 곰팡이가 표면에 생긴 것이다. 발효된 쥐눈이콩을 건조기를 사용하여 건조하였다. 이때, 온도를 35℃로 맞추고 12 ~ 15시간 동안 꾸준히 일정온도로 건조시켰다. 잘 건조된 쥐눈이콩의 성상으로는 바스락 거릴 정도로 완전히 건조되어 분이 일어날 정도이다.
First, Korean domestic bean was selected according to the selection criteria. The selected bean curd was immersed at room temperature for 10 ~ 15 hours for 3 hours in high temperature and 3 hours in low temperature. After the increase, the puppy was inoculated with yeast. The optimum temperature of the soybean at the time of inoculation with koji was 35 ~ 38 ℃, so the soybean was boiled at 38 ℃ ± 2 and the koji was inoculated. The husks inoculated with the yeast were fermented at 32 ~ 38 ℃ for 18 hours. Optimum Fermented Rats The characteristics of the beans are that the sticky threads are stretched between the beans, the fermented beans smell, the smell disappears, and the white mold appears on the surface. Fermented dry bean was dried using a drier. At this time, the temperature was adjusted to 35 캜 and dried at a constant temperature for 12 to 15 hours. The well-dried crust is so dry that the beans are so rusty that the beans are almost dry.
<1-3> 원료의 전처리 공정<1-3> Pretreatment of raw materials
원료의 전처리 공정은 다음과 같이 수행하였다.The pretreatment process of the raw materials was carried out as follows.
유황오리를 24시간 동안 정제수에 달여 열수 추출물을 제조하였다. 유근피를 24시간 동안 정제수에 달여 열수 추출물을 제조하였다. 밭마늘을 19시간 동안 정제수에 달여 열수 추출물을 제조하였다. 9회 법제 자죽염은 고운 분말형태로 하여 직접 사용하였다. 누룩 접종 후 발효과정을 거친 쥐눈이콩을 건조시켰다.
Sulfur duck was added to purified water for 24 hours to prepare hot water extract. The extracts of hot water extracts were prepared by suspending the yugi cakes in purified water for 24 hours. The field garlic was boiled in purified water for 19 hours to produce hot water extract. Bamboo salt was used in the form of fine powder and used directly. After the yeast inoculation, the soybeans were dried by a fermentation process.
<1-4> 원료의 혼합비 설정<1-4> Setting the mixing ratio of raw materials
전처리된 원료들은 다음의 혼합비로 혼합하였다.The pretreated raw materials were mixed at the following mixing ratios.
원료 혼합비에 대한 관능평가는 인산죽염촌(주) 직원들을 상대로 5점 척도 관능평가에 의해 실시하였다Sensory evaluation of raw material mixing ratio was carried out by 5 point scale sensory evaluation for employees of phosphoric acid bamboo salt village co.
싫어한다Extremely
I hate it.
좋아한다.Extremely
Likes.
그 결과, 조건 1은 밭마늘이 다른 혼합물에 비해 적어 죽염으로 인해 너무 짠맛을 느꼈으며, 조건 2는 조건 1보다 짠맛이 완화되었으나, 5종류의 원료가 잘 혼합되어 짜면서 복합적인 맛을 느꼈으며, 조건 3은 죽염이 다른 혼합물에 비해 많이 들어 있어 짠맛이 무척 강하였다. 따라서, 원료 혼합비의 최종 선정은 조건 2로 결정하였다.
As a result, the
<1-4> 원료의 가열 공정<1-4> Heating process of raw materials
숙성된 발효조성물의 미생물 등에 의한 오염을 방지하기 위한 열처리 공정을 수행하였다. 지방성분 분해로 인한 냄새성분의 휘발과 유효성분 유실을 주의하여 80 ~ 98℃로 약 30분간 가열 처리하였다.
A heat treatment process was performed to prevent contamination of the aged fermentation composition with microorganisms and the like. Care was taken for volatilization of the odor component due to decomposition of the fat component and loss of the active ingredient, followed by heating at 80 to 98 ° C for about 30 minutes.
<1-5> 발효조성물의 제조≪ 1-5 > Preparation of fermentation composition
죽염과 쥐눈이콩의 발효에 의해 생성된 발효조성물은 1차로 쥐눈이콩을 누룩과 함께 발효시켜 쥐눈이콩 발효콩을 만드는 단계, 및 2차로 쥐눈이콩 발효콩과 죽염, 유황오리, 유근피, 밭마늘 등과 함께 숙성시키는 단계를 거쳐 최종 발효조성물을 제조하였다. The fermentation composition produced by the fermentation of bamboo salt and the bean curd of soybean was firstly fermented with the yeast and the step of making the soybean fermented soybeans, and the second step was the fermentation of the soybean fermented soybean with bamboo salt, sulfur duck, Followed by aging to prepare a final fermentation composition.
구체적으로, 1차로 쥐눈이콩을 세척한 후 삶은 다음, 40℃의 일정한 온도로 식힌 다음, 누룩을 접종시켜 1차 발효시킨 후, 건조시킴으로써 발효 건조콩을 제조하였다. 그런 다음, 2차로 제조된 발효건조콩에 죽염, 유황오리, 유근피, 밭마늘 및 물을 혼합한 후 숙성시킨 후, 여과한 다음, 가열하여 발효액을 회수한 후, 2차 숙성시켜 최종 발효조성물을 제조하였다(도 1).
Specifically, the beans were firstly washed and then boiled, cooled at a constant temperature of 40 ° C, and then fermented to obtain fermented soybeans by first inoculation with yeast, followed by drying. Then, fermented dried soybeans, which were prepared in the second step, were mixed with bamboo salt, sulfur duck, yukeeji, field garlic, and water and then aged. After filtration, the fermented liquid was recovered by heating and then second- (Fig. 1).
<< 실시예Example 2> 죽염과 2> Bamboo salt 쥐눈이콩A little bean 발효에 의해 생성된 발효조성물의 일반성분 분석 General composition analysis of fermented composition produced by fermentation
일반성분시험법은 식품 중에 일반적으로 함유되어 있는 성분에 관한 시험법으로 식품의 규격, 순도의 검사 및 영양가를 평가하기 위하여 수분, 회분, 질소화합물, 탄수화물(당질) 및 지질의 시험방법과 열량계산법에 대하여 기재한 것이다. 보통 식품 중의 일반시험으로는 외관, 취미, 수분, 회분, 조단백질, 조지방 및 조섬유에 대하여 시험하고, 특별한 경우에는 비중, 아미노산성질소, 각종 당류 및 지질 등에 대하여 시험할 필요가 있다. 일반적으로 당질은 검체 100 g 중에서 수분, 조단백질, 조지방, 조섬유 및 회분의 양을 감하여 얻은 양으로서 표시하고 음식품 중의 일반성분의 시험결과는 보통 백분율로 표시한다. 하기 실험은 식품의약품안전청에서 고시하고 있는 식품공전에 따른 일반성분 분석법을 사용하였다.
The general component test method is a test method for ingredients generally contained in food. It is a test method for food standard, purity and nutritional value. It is used for testing of moisture, ash, nitrogen compounds, carbohydrates and lipids, . As a general test in ordinary foods, it is necessary to test for appearance, taste, moisture, ash, crude protein, crude fat and crude fiber, and in special cases, specific gravity, amino acid content, various saccharides and lipids. In general, carbohydrate is expressed as the amount obtained by subtracting the amount of moisture, crude protein, crude fat, crude fiber and ash from 100 g of the sample, and the test result of the common ingredient in food and drink is usually expressed as a percentage. The following experiment was carried out using the general component analysis according to the Food Code of the Food and Drug Administration.
<2-1> 당류 측정<2-1> Sugar measurement
시험용액은 다음과 같이 조제하였다. 구체적으로, 검체 약 5 g을 정확히 칭량하여 50 ml, 메스플라스크에 담았다. 그런 다음, 물 25 ml를 가하여 녹인 후 아세토니트릴로 50 ml까지 채웠다. 그런 다음, 0.45 um 멤브레인 필터로 여과한 것을 시험용액으로 사용하였다.Test solutions were prepared as follows. Specifically, about 5 g of the sample was precisely weighed and placed in a 50 ml volumetric flask. Then, 25 ml of water was added to dissolve, and then 50 ml of acetonitrile was added. The test solution was then filtered through a 0.45 um membrane filter.
표준용액은 다음과 같이 조제하였다. 구체적으로, Fructose, Glucose, Sucrose, Maltose의 표준품을 각각 100 ml, 메스플라스크에 정밀히 달아 물 50 ml로 녹인 후 아세토니트릴로 100 ml까지 채웠다.The standard solution was prepared as follows. Specifically, 100 ml of each standard of fructose, glucose, sucrose, and maltose was precisely weighed in a measuring flask and dissolved in 50 ml of water, and then filled up to 100 ml with acetonitrile.
측정기기로는 LC(Agilent 1200)를 사용하였으며, 컬럼은 Shodex Asahipak NH2P 50-4E를 사용하였다.LC (Agilent 1200) was used as the measuring device, and Shodex Asahipak NH2P 50-4E was used as the column.
검사결과(g/100g)를 하기의 식에 대입하였다.The test result (g / 100g) was substituted into the following equation.
당류(g/100g) = C×V/S×DSugar (g / 100g) = C x V / S x D
C : 검출농도(mg/L);C: detection concentration (mg / L);
V : 시험용액의 최종 부피(mL);V: final volume of test solution (mL);
S : 시료 채취량(g); 및S: Amount of sample (g); And
D : 시험용액의 희석배수.]
D: Dilution of test solution.]
<2-2> <2-2> 조단백질Crude protein 측정 Measure
검체의 분해는 다음과 같이 수행하였다. 구체적으로, 검체 약 1 g을 정밀하게 취하여 분해촉진제 2알을 넣었다(분해촉진재는 H2SO4와 K2SO4의 비율이 1.4 ~ 2.0 : 1). 그런 다음, 분해튜브에 진한 황산 12 mL를 첨가하여 검체의 지방 함량이 10% 이상이면 진한 황성 15 mL를 넣었다. 그런 다음, 420℃의 분해장치에서 45 ~ 60분간 분해하여 분해액의 색이 투명한 연푸른색 또는 투명한 노란색이 되면 상온으로 냉각하였다.The degradation of the specimen was performed as follows. Specifically, about 1 g of the sample was precisely taken and 2 pieces of the decomposition promoter were added (the ratio of H 2 SO 4 and K 2 SO 4 was 1.4 to 2.0: 1 for the decomposition promoter). Then add 12 mL of concentrated sulfuric acid to the digestion tube and add 15 mL of concentrated sulfuric acid if the fat content of the sample is 10% or more. Then, it was decomposed in a decomposition apparatus at 420 ° C for 45 to 60 minutes. When the color of the decomposition liquid became transparent pale blue or transparent yellow, it was cooled to room temperature.
증류 및 적정은 다음과 같이 수행하였다. 구체적으로, 질소자동분석장치에 실험용액이 담긴 킬달플라스크를 장착 후 자동 증류 및 적정장치를 이용하여 수행하였다. Distillation and titration were carried out as follows. Specifically, a Kjeldahl flask containing an experimental solution was mounted on an automatic nitrogen analyzer, and then an automatic distillation and titration apparatus was used.
이때, 단백질 분해장치로는 SOX 416 Macro을 사용하였고, 증류 및 적정장치로는 Gerhardt Vapodest 45s을 사용하였다.At this time, SOX 416 Macro was used as a proteolysis apparatus and Gerhardt Vapodest 45s was used as a distillation and titration apparatus.
적정된 수치를 하기의 식에 대입하여 조단백질 함량을 산출하였다.The crude protein content was calculated by substituting the titration value into the following equation.
조단백질(%) = 1.4007×(a-b)×(100/검체의 채취량(mg))×질소계수(%) = 1.4007 x (a-b) x (100 / sample weight (mg)) x Nitrogen Coefficient
a : 본시험에서 중화에 소요된 0.1N 황산의 mL수;a: the number of mL of 0.1 N sulfuric acid required for neutralization in this test;
b : 공시험에서 중화에 소요된 0.1N 황산의 mL수; 및b: the number of mL of 0.1 N sulfuric acid consumed for neutralization in the blank test; And
0.1N 황산 1 mL = 1.4007 mgN.
1 mL of 0.1 N sulfuric acid = 1.4007 mgN.
<2-3> <2-3> 조지방Crude fat 측정 Measure
검체 1 ~ 10 g을 정밀히 달아 지방추출관에 넣어 물을 가하여 약 11 mL로 하고 40 ~ 50℃로 가온한 후 흔들어 완전히 혼화하였다. 그런 다음, 암모니아수 1.5 mL(액이 산성인 경우 2.0 mL)를 가하여 혼화한 후 알코올 10 mL를 가하여 혼합하였다. 그런 다음, 에테르 25 mL를 가하여 가볍게 섞고 마개를 열어 에테르를 날려 보낸 후 다시 마개를 닫고 약 1분간 세게 흔들었다. 그런 다음, 이를 600 rpm에서 원심분리하거나 방치하여 상층액이 완전히 투명하게 되면 상층액을 미리 항량으로 한 삼각플라스크에 옮겼다. 그런 다음, 관내의 남은 액에 에테르 각 15 mLTlr 가하여 위와 같이 조작하였다. 그런 다음, 다시 에테르 15 mL씩으로 3회 추출하였다. 그런 다음, 관의 마개 유출구 및 깔때기를 에테르로 깨끗이 씻고 여액 및 씻은 액을 삼각플라스크에 합쳐 수욕상에서 용매를 날렸다. 그런 다음, 삼각플라스크를 100±2℃의 건조기에 넣고 항량이 될 때까지 건조하고 조지방의 함량을 하기의 식에 대입하여 산출하였다.1 ~ 10 g of specimen was precisely weighed and placed in a fat extraction tube. Water was added to make about 11 mL, heated to 40 ~ 50 ℃ and completely mixed by shaking. Then, 1.5 mL of ammonia water (2.0 mL when the liquid was acidic) was added thereto, followed by mixing, followed by mixing with 10 mL of alcohol. Then, add 25 mL of ether, mix gently, open the stopper, blow off the ether, close the stopper again, and shake hard for about 1 minute. Then, it was centrifuged or left at 600 rpm, and when the supernatant liquid became completely transparent, the supernatant was transferred to an Erlenmeyer flask. Then, 15 mL of the ether was added to the remaining solution in the tube, and the above operation was carried out. Then, it was extracted three times with 15 mL of ether again. Then, the outlet of the tube and the funnel were cleaned with ether, and the filtrate and the washed solution were combined with Erlenmeyer flask and the solvent was blown off in a water bath. Then, the Erlenmeyer flask was placed in a drier at 100 ± 2 ° C, dried until the weight became constant, and the content of crude fat was substituted into the following equation.
조지방(%) = (W1-W2)/S×100Crude fat (%) = (W1-W2) / S * 100
W1 : 용기의 무게(g);W1: weight of container (g);
W2 : 건조후 용기의 무게(g); 및W2: weight of container after drying (g); And
S : 검체의 채취량(g).
S: Weight of sample (g).
<2-4> 트랜스지방 측정<2-4> Trans fat measurement
시험용액은 다음과 같이 조제하였다.Test solutions were prepared as follows.
구체적으로, 검체를 일정량 칭량하고 원통여과지에 넣고 105℃에서 건조한 후, 속시레추출기에서 8시간 추출한 다음, 수기의 에테르를 수욕상에서 모두 증발시켰다. 그런 다음, 100℃에서 항량을 시키고 칭량하여 조지방함량을 구하였다. 그런 다음, 지질을 0.025g 정도 칭한 후, 0.5N 메탄올성 수산화나트륨용액 1.5 mL 가한 다음, IS 1 mL를 첨가하였다. 그런 다음, 질소를 불어넣고 즉시 뚜껑을 닫고 혼합한 후, 100℃ heating brock에서 5분간 가온한 다음, 냉각 후 14% 트리플루오르보란메탄올용액 2 mL 가하였다. 그런 다음, 질소를 불어넣고 즉시 뚜껑을 닫고 혼합한 후, 100℃ heating brock에서 30분간 가온한 다음, 30 ~ 40℃로 냉각 후 이소옥탄 1 mL 가하였다. 그런 다음, 질소를 불어넣고 즉시 뚜껑을 닫고 이 온도에서 격렬히 진탕한 후, 포화 염화나트륨용액 5mL 가하고 질소 불어넣은 후 뚜껑덮고 진탕하였다. 그런 다음, 상온으로 냉각 후 이소옥탄층을 새유리튜브에 취한 후, 무수황산나트륨으로 탈수한 다음, 질소를 불어넣고 이것을 시험용액으로 사용하였다.Specifically, the sample was weighed in a predetermined amount, placed in a cylindrical filter paper, dried at 105 ° C, extracted for 8 hours with a syringe extractor, and evaporated in a water bath. Then, a constant amount was added at 100 캜 and weighed to determine the crude fat content. Then, the lipid was called 0.025 g, and then 1.5 mL of 0.5 N methanolic sodium hydroxide solution was added, followed by 1 mL of IS. Then, nitrogen was blown and immediately the lid was closed. After mixing, the mixture was heated at 100 ° C in a heating brock for 5 minutes. After cooling, 2 mL of a 14% trifluoro-borane methanol solution was added. Then, nitrogen was blown and immediately the lid was closed and mixed. The mixture was heated at 100 ° C for 30 minutes in a heating brock, cooled to 30 to 40 ° C, and 1 ml of isooctane was added. Then, nitrogen was blown in and immediately the lid was closed. After shaking vigorously at this temperature, 5 mL of a saturated sodium chloride solution was added, and the mixture was blown with nitrogen, covered with a lid and shaken. Then, after cooling to room temperature, the iso-octane layer was taken in a new glass tube, dehydrated with anhydrous sodium sulfate, and then nitrogen was blown into it and used as a test solution.
표준용액은 SUPELCO사에서 나온 SIPELCO 37 Component FAME Mix(Part NO, 47885-U)를 사용하였고, 내부표준용액은 Undecanoic acid를 40 mg을 취하여 이소옥탄으로 100 mL 정용하여 사용하였다.The standard solution used was a SIPELCO 37 Component FAME Mix (Part NO, 47885-U) from SUPELCO, and 40 mg of undecanoic acid was used as an internal standard solution.
측정기기는 GC(Perkin Elmer GC-Clarus 600)를 사용하였고, 컬럼은 SP-2560을 사용하였다. GC (Perkin Elmer GC-Clarus 600) was used as the measuring apparatus, and SP-2560 was used as the column.
검사결과(g/100g)를 하기의 식에 대입하였다.The test result (g / 100g) was substituted into the following equation.
포화지방(g/100g 식품) = 조지방함량(g/100g 식품)×포화지방산함량(g/100g 지방산)/100; 및Saturated fat (g / 100g food) = crude fat content (g / 100g food) x saturated fatty acid content (g / 100g fatty acid) / 100; And
트랜스지방(g/100g 식품) = 조지방함량(g/100g 식품)×트랜스지방산함량(g/100g 지방산)/100.
Trans fat (g / 100g food) = crude fat content (g / 100g food) x trans fatty acid content (g / 100g fatty acid) / 100.
<2-5> 콜레스테롤 측정<2-5> Cholesterol measurement
시험용액은 다음과 같이 조제하였다.Test solutions were prepared as follows.
구체적으로, 검체 1 ~ 10 g에 물 약 30 mL와 5 g 콜레스탄 1 mL 첨가후 균질화(검체량은 콜레스테롤함량 20 ~ 1000 mg/100 g 취함)하였다. 그런 다음, 이 액을 분액여두에 옮겨 클로로포름:메탄올(2:1) 200 mL, 약 5분간 진탕 혼합 추출한 후, 방치한 다음, 클로로포름층을 cln한 후 검액 잔류물에 다시 2회 반복 추출하였다. 추출한 클로로포름층을 합하여 0.5% 수산화나트륨 용액 100 mL로 세척한 후, 무수황산나트륨으로 탈수, 여과한 다음, 40℃ 이하에서 감압농축한 후, 잔류물에 2N 수산화칼륨 에탄올용액 20 mL 가하였다. 환류냉각기를 붙여 85℃에서 1시간 비누화하여 냉각한 후, 물 약 20 mL와 함께 분액여두에 옮긴 다음, 에틸에테르로 약 20 mL씩 4회 추출하였다. 에테르 추출물을 모두 합하여, 물 약 20 mL씩으로 세척한 후, 페놀프탈레인 지시약으로 홍색이 나타나지 않을 때까지 세척한 다음, 에테르층을 무수황산나트륨으로 탈수, 여과 후 감압농축한 다음, 건고물을 헥산 2 mL에 녹여 시험용액으로 사용하였다.Specifically, about 30 mL of water and 1 mL of 5 g cholestane were added to 1 to 10 g of a sample, and homogenized (a cholesterol content of 20 to 1000 mg / 100 g was taken as a sample amount). Then, this solution was transferred to a separatory funnel, and 200 mL of chloroform: methanol (2: 1) was mixed and extracted with shaking for about 5 minutes, and then allowed to stand. After the chloroform layer was clinched, the solution was repeatedly extracted twice. The combined chloroform layers were combined and washed with 100 mL of 0.5% sodium hydroxide solution. The mixture was dehydrated with anhydrous sodium sulfate, filtered, concentrated under reduced pressure at 40 ° C or lower, and 20 mL of 2N potassium hydroxide ethanol solution was added to the residue. After refluxing, the mixture was saponified at 85 ° C for 1 hour, cooled, transferred to a separatory funnel along with about 20 mL of water, and extracted with ethyl acetate four times with about 20 mL each. The ether extracts were combined and washed with about 20 mL of water, washed with phenolphthalein indicator until no red color appeared, and the ether layer was dehydrated with anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was dissolved in 2 mL of hexane Dissolved and used as a test solution.
콜레스테롤 표준용액은 콜레스테롤 25 mg을 헥산에 녹여 50 mL로 사용하였고, 내부 표준용액은 5a-콜레스탄 25 mg을 헥산에 녹여 100 mL로 사용하였다.Cholesterol standard solution was prepared by dissolving 25 mg of cholesterol in hexane to 50 mL, and using 25 mL of 5a-cholestane as an internal standard solution in 100 mL of hexane.
측정기기는 GC(Perkin Elmer GC-Clarus 600)를 사용하였고, 컬럼은 HP-5를 사용하였다. GC (Perkin Elmer GC-Clarus 600) was used as the measuring apparatus and HP-5 was used as the column.
검사결과(mg/100g)를 하기의 식에 대입하였다.The test result (mg / 100g) was substituted into the following equation.
콜레스테롤(mg/100g) = C×V/S×D×1/10Cholesterol (mg / 100 g) = C 占 V / S 占 D 占 1/10
C : 검출농도(mg/L);C: detection concentration (mg / L);
V : 시험용액의 최종 부피(mL);V: final volume of test solution (mL);
S : 시료 채취량(g); 및S: Amount of sample (g); And
D : 시험용액의 희석배수.
D: Dilution of test solution.
<2-6> 나트륨 측정<2-6> Measurement of sodium
시료 전처리(건식 회화법)는 다음과 같이 수행하였다. The sample pretreatment (dry method) was carried out as follows.
구체적으로, 검체(건조물로서 5 ~ 20 g에 상당하는 양)를 도가니에 취한 후 건조시킨 후 탄화시킨 다음, 450℃에서 회화(20시간)시켰다. 회분을 물로 적시고 염산 3 mL를 가한 후, 수욕상에서 건조시킨 다음, 염산 2 mL을 가하고 가온하여 녹인 후, 여지에 여과하고 물로 50 mL로 정용하여 시험용액으로 사용하였다.Specifically, a specimen (an amount corresponding to 5 to 20 g as a dried product) was taken in a crucible, dried and carbonized, and then calcined at 450 ° C for 20 hours. The ash was wetted with water, 3 mL of hydrochloric acid was added, and the mixture was dried in a water bath. Then, 2 mL of hydrochloric acid was added and dissolved by heating. The mixture was filtered through a filter paper and 50 mL of water was used as a test solution.
표준용액은 다음과 같이 조제하였다.The standard solution was prepared as follows.
구체적으로, 나트륨은 나트륨 표준용액 1,000 ug/mL을 3차 증류수를 사용하여 0.0 ppm, 1.0 ppm, 5.0 ppm, 10.0 ppm으로 희석하여 STD1, STD2, STD3, STD4로 표준용액으로 사용하였다. 중금속 분석에 사용한 모든 초자는 5% HNO3 용액에 24시간 침적시켜 오염물질을 제거한 후 3차 증류수로 여러번 행궈 건조시킨 다음 사용하였다.Specifically, sodium was used as a standard solution for STD1, STD2, STD3 and STD4 by diluting 1,000 ug / mL of sodium standard solution to 0.0 ppm, 1.0 ppm, 5.0 ppm, and 10.0 ppm with tertiary distilled water. All the piglets used for the analysis of heavy metals were immersed in 5% HNO3 solution for 24 hours to remove pollutants, and then lapped with third distilled water several times to dry.
측정기기는 유도결합 플라즈마 방출분광기(ICP-OES, Perkin-Elmer OPTIMA 7000 DV)를 사용하였다. The measurement instrument was an inductively coupled plasma emission spectrometer (ICP-OES, Perkin-Elmer OPTIMA 7000 DV).
시험결과(mg/100g)를 하기의 식에 대입하였다.The test result (mg / 100g) was substituted into the following equation.
Na 농도(mg/kg) = 기기측정농도(mg/L)×최종액량(mL)/검체량(g)×희석배수
Na concentration (mg / kg) = instrumental concentration (mg / L) × final volume (mL) / sample volume (g) × dilution factor
<2-7> 수분 측정<2-7> Moisture measurement
수분측정은 상압가열건조법을 이용하여 측정하였다.Moisture content was measured by atmospheric pressure heating drying method.
구체적으로, 미리 가열하여 항량으로 한 칭량접시에 검체 3 ~ 5 g을 정밀히 칭량(단, 건조가 어려운 검체인 경우에는 20매쉬 정제해사 20 g과 유리봉을 넣어 항량이 되게 하고 이에 검체를 넣어 잘 섞은 후 유리봉은 그대로 넣어둠)하였다. 뚜껑을 약간 열어 넣고 시험법 적용범위 항의 적용범위에 따라 규정된 온도의 건조기에 넣어 3 ~ 5시간 건조하였다. 건조 후 데시케이터 중에서 약 30분간 식히고 칭량하였다. 다시 칭량접시를 1 ~ 2시간 건조하여 항량이 될 때까지 같은 조작을 반복하였다.Specifically, weigh accurately 3 to 5 g of specimen in a weighing dish which has been preliminarily heated to a constant weight (but if it is difficult to dry, 20 g of refined margarine 20 g and a glass rod are put into a constant volume, After mixing, the glass rods were left in place. The lid was slightly opened and placed in a drier of the prescribed temperature according to the application range of the test method application range and dried for 3 to 5 hours. After drying, it was cooled in a desiccator for about 30 minutes and weighed. The weighing dish was again dried for 1 to 2 hours and the same operation was repeated until the weight became constant.
시험결과(%)를 하기의 식에 대입하였다.The test result (%) was substituted into the following equation.
수분(%) = (b-c)/(b-a)×100Water (%) = (b-c) / (b-a) 100
a : 칭량접시의 무게(g);a: weight of the weighing dish (g);
b : 칭량접시와 검체의 무게(g); 및b: Weight of weighing dish and sample (g); And
c : 건조 후 항량이 되었을 때의 무게(g).
c: Weight after drying (g).
<2-8> 화분 측정<2-8> Measuring pots
도가니의 항량은 다음과 같이 수행하였다.The weight of the crucible was measured as follows.
구체적으로, 깨끗한 도가니를 회화로에서 600℃이상으로 여러 시간 강하게 가열 후 데시케이터에 옮겨 실온으로 식힌 다음 칭량하며, 다시 2시간 강하게 가열하여 건조 칭량하고 이 조작을 항량이 될 때까지 반복하였다.Specifically, a clean crucible was heated in a painting furnace at a temperature of 600 ° C or higher for several hours, transferred to a desiccator, cooled to room temperature, weighed, heated again for 2 hours and then weighed dry and the operation was repeated until the weight became constant.
회화는 다음과 같이 수행하였다.The painting was carried out as follows.
구체적으로 전처리 이후, 용기를 그대로 회화로에 옮겨 550 ~ 600℃에서 백색 ~ 회백색의 회분이 얻어질 때까지 계속 가열한 다음, 회화가 끝난 다음, 가열을 그치고 그대로 식혀 온도가 약 200℃로 되었을 때 데시케이터에 옮겨 식힌 후 칭량하였다.Specifically, after the pretreatment, the container was transferred directly to a painting furnace, and the mixture was continuously heated at 550 to 600 ° C. until a white to off-white ash was obtained, and after the painting was completed, the heating was stopped and the mixture was cooled to about 200 ° C. Transferred to a desiccator, allowed to cool, and weighed.
시험결과(%)를 하기의 식에 대입하였다.The test result (%) was substituted into the following equation.
회분(%) = (W1-W2)/S×100Ash (%) = (W1-W2) /
W1 : 도가니의 무게(g);W1: weight of crucible (g);
W2 : 회화 후 도가니무게(g); 및W2: Crucible weight after painting (g); And
S : 검체량(g).
S: Amount of specimen (g).
죽염과 쥐눈이콩의 발효에 의해 생성된 발효조성물의 구간별 일반성분 분석 결과는 다음과 같이 나타내었다.The results of the general compositional analysis of the fermented composition produced by the fermentation of bamboo salt and the bean curd soybean were as follows.
(6개월 숙성)Fermentation composition
(Aged 6 months)
<< 실시예Example 3> 죽염과 3> Bamboo salt 쥐눈이콩A little bean 발효에 의해 생성된 발효조성물의 이화학적 실험 Physicochemical experiment of fermented composition produced by fermentation
<3-1> 죽염의 <3-1> Bamboo salt pHpH 및 And ORPORP 측정 Measure
증류수 100 ml에 죽염 10 g을 넣고 오차의 범위를 줄이기 위해 교반기로 10분 이상 교분시켜 잘 녹인 다음 ORP 값이 가장 안정되었을 때 ORP 및 pH 수치를 기록하였다.10 g of bamboo salt was added to 100 ml of distilled water, and the mixture was mixed well with a stirrer for 10 minutes or more in order to reduce the error range. The ORP and the pH value were recorded when the ORP value was the most stable.
그 결과, 죽염의 pH는 10.5이고, ORP는 -400 mV를 나타내었다.
As a result, the pH of bamboo salt was 10.5 and the ORP was -400 mV.
<3-2> 발효조성물의 ≪ 3-2 > pHpH 및 And ORPORP 측정 Measure
죽염과 쥐눈이콩의 발효에 의해 생성된 발효조성물 샘플 시료, 6개월 숙성시료, 3년 이상 숙성 시료를 각각 준비하고 ORP 값이 가장 안정되었을 때 ORP 및 pH 수치를 기록하였다.A sample of the fermented composition produced by fermentation of bamboo salt and bean curd beans, a 6-month aged sample, and a 3-year aged sample were prepared, and ORP and pH values were recorded when the ORP value was the most stable.
그 결과, 발효조성물 담금샘플의 pH는 6.67이고 ORP는 12.3 mV를 나타내었고, 발효조성물 6개월 숙성시료의 pH는 5.74이고 ORP는 65.6 mV를 나타내었으며, 발효조성물 3년 숙성시료의 pH는 5.25이고 ORP는 93.8 mV를 나타내었다.
As a result, the pH of the immersed sample of the fermented composition was 6.67 and the ORP was 12.3 mV. The pH of the aged sample for 6 months was 5.74 and the ORP was 65.6 mV. The pH of the fermented composition aged 3 years was 5.25 ORP was 93.8 mV.
<3-3> 발효조성물의 염도 측정<3-3> Salinity Measurement of Fermentation Composition
죽염과 쥐눈이콩의 발효에 의해 생성된 발효조성물 샘플 시료, 6개월 숙성시료, 3년 이상 숙성 시료를 각각 온도에 따른 오차를 고려하여 염도계를 이용하여 염도를 측정하였다.Salinity was measured using a salinity meter, taking into consideration the temperature - dependent errors of the fermented composition sample, six - month aged sample, and three - year aged sample produced by the fermentation of bamboo salt and rice husk.
그 결과, 발효조성물 담금 샘플의 염도는 22.6%이고, 발효조성물 6개월 숙성시료의 염도는 35%이며, 발효조성물 3년 숙성시료의 염도는 40%를 나타내었다.
As a result, the salinity of the sample immersed in the fermented composition was 22.6%, the salinity of the fermented composition aged 6 months was 35%, and the salinity of the fermented composition aged 3 years was 40%.
<< 실시예Example 4> 죽염과 4> Bamboo salt 쥐눈이콩A little bean 발효에 의해 생성된 발효조성물의 Of the fermentation composition produced by fermentation 시험관내(In vitro In vitroIn vitro )모델에서) In the model 기능성 분석 Functional Analysis
<4-1> 시료의 준비<4-1> Preparation of sample
각 시료는 하기와 같이 분류하였으며, 이들 시료는 모두 인산죽염촌을 통해 제공받았다.Each sample was classified as follows, and all of these samples were supplied through a phosphate buffered saline solution.
A : 발효된 쥐눈이콩 18.52 g에 50 mL의 물을 가하여 추출;A: Extracted by adding 50.5 mL of water to 18.52 g of fermented twigs;
B : 발효된 쥐눈이콩 20 kg에 천일염 20 kg, 및 물 54 L를 이용하여 만든 발효 조성물;B: fermented composition prepared by using 20 kg of sun dried salt and 54 L of water in 20 kg of fermented twigs;
C : 발효된 쥐눈이콩 20 kg에 인산죽염 20 kg, 및 물 54 L를 이용하여 만든 발효 조성물;C: fermented composition prepared by using 20 kg of phosphoric acid bamboo salt and 54 L of water in 20 kg of fermented twigs;
D : 발효된 쥐눈이콩 20 kg에 인산죽염 20 kg, 및 유근피 1.05 kg, 밭마늘 1.4 kg, 유황오리 2.6 kg을 60 L의 물에서 열수 추출한 후 만든 발효 조성물.
D: A fermented composition prepared by hot water extraction of 20 kg of fermented dried bean curds, 20 kg of phosphoric acid bamboo salt, 1.05 kg of yuukeeji, 1.4 kg of field garlic and 2.6 kg of sulfur duck, in 60 L of water.
<4-2> 총 페놀 함량의 분석<4-2> Analysis of Total Phenol Content
총 페놀 함량은 시료 1 mL를 취하여 2%(w/v) Na2CO3 용액 1 mL를 가하고 3분간 방치한 후, 50% 폴린-시오칼토9Folin-Ciocalteu) 시약 0.2 mL를 첨가하여 반응시켜 30분간 상온에서 방치하였다. 이 혼합물을 10분간 13,400×g에서 원심분리한 후, 상층액 1 mL를 취하여 750 nm에서 spectrophotometer(Shimadzu UV-1601, Kyoto, Japan)를 이용하여 흡광도를 측정하였다. 총 페놀 함량은 갈산(gallic acid)를 이용하여 작성한 표준곡선으로 mg/g GAE(gallic acid equivalents) 단위로 나타내었다.The total phenol content was determined by taking 1 mL of the sample, adding 1 mL of 2% (w / v) Na 2 CO 3 solution and allowing to stand for 3 minutes, and then adding 0.2 mL of 50% Folin-Ciocalteu reagent And allowed to stand at room temperature for several minutes. The mixture was centrifuged at 13,400 × g for 10 minutes, and 1 mL of the supernatant was taken and absorbance was measured at 750 nm using a spectrophotometer (Shimadzu UV-1601, Kyoto, Japan). The total phenolic content was expressed in mg / g GAE (gallic acid equivalents) as a standard curve using gallic acid.
그 결과, 쥐눈이콩에 천일염을 첨가하여 만든 조성물 B가 가장 높은 함량을 보였고, 그 다음으로 죽염을 첨가하여 만든 조성물 C, 그 다음으로 쥐눈이콩 자체 발효물 A와 죽염 및 밭마늘, 유황오리, 유근피를 함유한 D가 동일한 수준의 함량을 나타내었다(도 6).
As a result, Composition B prepared by adding sun salt to chicken legs showed the highest content, followed by Composition C prepared by adding bamboo salt, followed by rice bran self fermentation A, bamboo salt and field garlic, sulfur duck, Showed the same level of D (FIG. 6).
<4-3> <4-3> DPPHDPPH 라디칼Radical 소거 활성의 분석 Analysis of scavenging activity
DPPH 라디칼 소거능은 시료 0.2 mL에 0.04 mM DPPH 용액 0.8 mL를 가한 후 상온에서 30분간 반응시켜 517 nm에서 흡광도를 측정하였다. 각 시료의 DPPH 라디칼 소거능은 아래의 식으로 계산하여 백분율로 나타내었다. The DPPH radical scavenging activity was measured by adding 0.8 mL of 0.04 mM DPPH solution to 0.2 mL of the sample, reacting at room temperature for 30 minutes, and measuring the absorbance at 517 nm. The DPPH radical scavenging activity of each sample was calculated by the following formula and expressed as a percentage.
DPPH 라디칼 소거활성=(1-B/A)×100DPPH radical scavenging activity = (1-B / A) x 100
A: 무처리구 흡광도; 및A: Absorbance of untreated water; And
B: 시료첨가구 흡광도.B: Absorbance of sample.
그 결과, 모든 조성물에서 농도 의존적으로 활성이 증가하는 결과를 나타내었으며, 라디칼을 50% 저해하는 시료의 농도를 의미하는 IC50값을 계산한 결과, 조성물 B의 경우 7.5 mg으로 DPPH 라디칼 소거능이 가장 강력한 것으로 나타났으며, D는 11.2 mg, C는 11.8 mg, A는 15.7 mg의 순으로 나타났다.As a result, the activity of each composition was increased in a concentration-dependent manner. The IC 50 value indicating the concentration of the sample inhibiting 50% of the radical was calculated. As a result, in the case of the composition B, the DPPH radical scavenging ability was 7.5 mg D was 11.2 mg, C was 11.8 mg, and A was 15.7 mg in that order.
1)A : 발효된 쥐눈이콩; B : 발효된 쥐눈이콩 + 천일염; C : 발효된 쥐눈이콩 + 인산죽염; 및 D : 발효된 쥐눈이콩 + 인산죽염 + 유근피 + 밭마늘 + 유황오리. 1) A: Fermented chicken legs; B: Fermented chicken legs + sun salt; C: Fermented chicken legs + phosphoric acid bamboo salt; And D: fermented wheat bean + phosphoric acid bamboo salt + yuga pea + field garlic + sulfur duck.
2)데이타는 평균 ± 표준편차 (n=3); 2) Data are mean ± standard deviation (n = 3);
3)P<0.05에서 유의적 차이는 열 내에 다른 첨자 (a-d, A-D)로 나타냄; 및 3) Significant differences at P <0.05 are indicated by different subscripts (ad, AD) in the column; And
4)IC50 (mg/mL)은 라디칼의 50% 소거에 요구되는 mg/mL의 농도.
4) IC 50 (mg / mL) is the concentration of mg / mL required for 50% removal of the radical.
<4-4> <4-4> ORACORAC 활성의 분석 Analysis of activity
퍼옥시 라디칼(Peroxy radical)의 생성과 소멸에 의한 형광의 감소율 변화에 대한 시료의 항산화 활성은 퍼옥시 라디칼 소거능(peroxyl radical scavenging capacity, ORACROO) 분석법을 이용하여 측정하였다. 과산화 라디칼의 생성을 위해 5 mM 2, 2'-azobis(2-methylpropionamidine) dihydrochloride(AAPH)를 사용하였고, 형광표준 용액은 40 nM fluorescent를 제조하여 GENios fluorescence plate reader(Tecan, Salzburg, Austria)로 여기 파장(excitation wavelength) 485 nm, 방출 파장(emission wavelength) 535 nm에서 측정하였다. 결과는 vitamin E 수용성 유도체인 Trolox(6-hydroxy-2,5,7,8- tetramethylchroman-2-carbonyl acid) 1 μM에 의해 보호된 curve area와 비교하여 검체 1 g당 μM Trolox equivalent(μM TE/g)로 나타내었다.The antioxidative activity of the sample against the change of the fluorescence reduction rate due to the formation and disappearance of the peroxy radical was measured by the peroxyl radical scavenging capacity (ORACROO) assay. For the generation of peroxidation radicals, 5 mM 2, 2'-azobis (2-methylpropionamidine) dihydrochloride (AAPH) was used and 40 nM fluorescent standard solution was prepared and applied to GENios fluorescence plate reader (Tecan, Salzburg, Austria) An excitation wavelength of 485 nm, and an emission wavelength of 535 nm. The results were compared with the curve area protected by 1 μM Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carbonyl acid) g).
그 결과, 네 가지 모든 시료에서 농도 의존적인 활성증가 경향을 보였다. 각 농도별 비교에서 1, 5, 10 μg/mL 농도에서는 네 가지 시료 모두 유사한 활성을 나타내었고 최고농도인 50 μg/mL에서는 C시료에서 13.3으로 나타나 가장 높은 활성을 보였으며, A와 D에서 각각 6.9와 6.6, B에서 5.9 TE의 수준으로 나타났다(도 7).
As a result, the concentration-dependent increase in activity tended to be observed in all four samples. At the concentrations of 1, 5, and 10 μg / mL, the four samples exhibited similar activity, and the highest activity was observed at the highest concentration of 50 μg / mL (13.3 in the C sample) 6.9 and 6.6, and B to 5.9 TE (FIG. 7).
<4-5> <4-5> CACCAC (( CellularCellular antioxidantantioxidant capacitycapacity ) 활성의 분석) Analysis of activity
HepG2 세포를 이용한 살아 있는 세포 내에서 시료의 항산화 활성 측정을 위한 CAC assay는 DCFH-DA 분석법을 변형하여 측정하였다. 96-웰 플레이트(well plate)에서 HepG2 5×104 cells/mL을 37°C, 5% CO2 인큐베이터(incubator)에서 10% 소태아혈청(fetal bovine serum, FBS), 1% 페니실린/스트렙토마이신(penicillin/streptomycin)을 함유하는 Dulbecco's modified Eagle's medium(DMEM)으로 배양하였다. 24시간 후 배지를 제거하고 형광에 안정한 HBSS(Hank's balanced salt solution)를 각 well에 200 μL 분주한 후 최종 농도가 100 μg/mL이 되도록 각 시료를 처리하여 30 분 동안 배양하였다. 배양 후에 HBSS로 세척하고, HBSS 200 μL에 퍼옥시 라디칼(peroxyl radical) 발생을 위해 80 mM AAPH 2 μL를 가하여 30 분 동안 배양하였다. 형광 프로브(probe)로 40 mM DCFH-DA 2 μL를 가하고 빛을 차단하여 30 분 동안 배양한 후 GENios fluorescence plate reader(Tecan Trading AG, Salzburg, Austria)를 이용하여 여기 파장(excitation wavelength) 485 nm, 방출 파장(emission wavelength) 535 nm에서 형광의 발생 정도를 측정하였다. 음성대조군(negative control)은 DCFH-DA만을 처리하였으며, 양성대조군(positive control)에는 AAPH와 DCFH-DA를 처리하였으며 대조군의 형광값을 100%로 하여 각 시료와 AAPH의 상대적인 형광값을 비교하였다.The CAC assay for measuring the antioxidative activity of samples in living cells using HepG2 cells was determined by modifying the DCFH-DA assay. In a 96-well plate, 5 × 10 4 cells / mL of HepG2 was incubated at 37 ° C in a 5% CO 2 incubator with 10% fetal bovine serum (FBS), 1% penicillin / streptomycin penicillin / streptomycin) in Dulbecco's modified Eagle's medium (DMEM). After 24 hours, the medium was removed and 200 μL of fluorescence-stable Hank's balanced salt solution (HBSS) was dispensed into each well. Each sample was treated with a final concentration of 100 μg / mL and incubated for 30 minutes. After incubation, the cells were washed with HBSS, and 2 μL of 80 mM AAPH was added to 200 μL of HBSS for peroxyl radical generation, followed by incubation for 30 minutes. After incubation for 30 min with excitation of light, 40 μM DCFH-DA was added to the fluorescent probe. The excitation wavelength was adjusted to 485 nm using a GENios fluorescence plate reader (Tecan Trading AG, Salzburg, Austria) Emission wavelength The degree of fluorescence was measured at 535 nm. AAPH and DCFH-DA were treated for positive control and 100% for control, respectively, and the relative fluorescence values of AAPH and AAPH were compared.
그 결과, AAPH를 처리하지 않은 음성 대조군(negative control)의 활성을 100%로 했을 때 시료를 처리하지 않고 AAPH만을 처리한 양성 대조군(positive control)이 150%인데 반해 네 가지 시료 모두에서 유의적으로 높은 CAC 활성을 보였다. 각 시료별 농도간의 유의적 차이는 나타나지 않았으며 모든 농도의 수준은 NC와 동일한 수준인 것으로 나타났다(도 8).
As a result, when the activity of the negative control without AAPH was 100%, the positive control treated with AAPH alone was not treated with 150% of the sample, High CAC activity. There was no significant difference between the concentrations of each sample and all concentrations were at the same level as NC (FIG. 8).
<4-6> <4-6> DNADNA 손상 damaged 억제능의Inhibitory 분석 analysis
신선한 전혈 5 mL를 histopaque 1077을 이용해 백혈구를 분리한 후 본 실험에 사용하였다. 준비된 백혈구 세포에 시료를 처리한 후 37℃에서 30분간 반응시켰다. 그 후 백혈구를 PBS로 세척하고 인위적으로 산화적 스트레스를 유발하기 위하여 200 μM H2O2를 4℃에서 5분간 반응시키며, 반응이 끝난 후 PBS로 세척하였다. 양성 대조군(Positive control)은 시료 대신 1% DMSO를 처리 후 200 μM H2O2를 처리하였다. Comet assay 측정을 위해 반응을 끝낸 백혈구를 75 μL의 0.7% LMA과 섞은 후, 1.0% NMA가 전코팅(precoating)된 슬라이드(slide) 위로 현탁액이 골고루 분산되게 한 후 커버 글래스(cover glass)로 덮어 4℃ 냉장고에 보관하였다. Gel이 굳으면 커버 글래스를 벗기고 그 위에 다시 0.7% LMA 용액 75 μL로 한 겹 더 덮었으며 미리 준비해 둔 차가운 alkali lysis buffer(2.5 M NaCl, 100 mM Na2EDTA, 10 mM tris)에 사용 직전에 1% Triton X-100을 섞은 후 슬라이드를 담가 저온, 암실에서 1시간 동안 침지시켜 DNA의 이중가닥(double strand)을 풀어주었다. 용해(Lysis)가 끝난 후, 슬라이드를 전기영동 수조에 배열하고 4℃의 차가운 electrophoresis buffer(300 mM NaOH, 10 mM Na2EDTA, pH>13)를 채워 20분 동안 unwinding 시켜 DNA의 alkali labile sites가 드러나게 한 후 25 V/300±3 mA의 전압을 걸어 20분간 전기영동을 실시하였다. 빛에 의해 DNA가 부가적으로 손상되는 것을 방지하기 위해 위의 과정은 어두운 암실 조건에서 처리하였으며 전기영동이 끝난 후 0.4 M Tris buffer(pH 7.4)에 5분씩 담가 세척하는 과정을 3회 반복하여 슬라이드를 건조시키고 20 μL/mL 농도의 브롬화 에디듐(ethidium bromide)으로 핵을 염색하여 cover slip으로 덮은 뒤 형광현미경(Leica, Wetzlar, Germany) 상에서 관찰하였다. CCD 카메라(Nikon, Tokyo, Japan)를 통해 보내진 각각의 세포핵 이미지는 Komet 5.0 comet image analyzing system (Kinetic Imaging, Liverpool, UK)이 설치된 컴퓨터를 통해 분석하였다. 백혈구의 과산화수소(hydrogen peroxide)에 의한 DNA 손상 및 미더덕 추출물에 의한 손상억제 정도는 핵으로부터 이동해서 꼬리 부분으로 떨어져 나간 꼬리 부분 내 DNA %함량을 측정하여 100%로 환산하여 계산하였다. 각각의 처리구에서 2개의 slide를 만들어 각각 100개 세포의 DNA 손상 정도를 측정하고 각 처리구는 2회 반복 실험하였다.5 mL of fresh whole blood was separated from leukocytes using histopaque 1077 and used in this experiment. The prepared leukocyte cells were treated with a sample and reacted at 37 ° C for 30 minutes. Then, the leukocytes were washed with PBS and 200 μM H2O2 was reacted at 4 ° C for 5 minutes to induce oxidative stress artificially. After the reaction, the cells were washed with PBS. Positive control was treated with 1% DMSO instead of sample and 200 μM H2O2. For the Comet assay, the reaction was completed by mixing the reacted leukocytes with 75 μL of 0.7% LMA. The suspension was then spread over a precoated slide with 1.0% NMA and covered with a cover glass And stored in a refrigerator at 4 ° C. When the gel was hardened, the cover glass was peeled off and a layer of 75 μL of a 0.7% LMA solution was further coated thereon. To the cold alkali lysis buffer (2.5 M NaCl, 100 mM Na 2 EDTA, 10 mM tris) After mixing X-100, the slide was immersed in a dark room at room temperature for 1 hour to loosen the double strand of DNA. After lysis, the slides were placed in an electrophoresis bath and filled with cold electrophoresis buffer (300 mM NaOH, 10 mM Na 2 EDTA, pH> 13) at 4 ° C and unwound for 20 minutes to reveal alkaline labile sites of DNA Then, a voltage of 25 V / 300 3 mA was applied and electrophoresis was performed for 20 minutes. In order to prevent DNA from being damaged by light, the above procedure was carried out in dark dark room conditions. After the electrophoresis was completed, washing was repeated 3 times in 0.4 M Tris buffer (pH 7.4) And the nuclei were stained with ethidium bromide at a concentration of 20 μL / mL, covered with a cover slip, and observed under a fluorescence microscope (Leica, Wetzlar, Germany). Each nucleus image sent through a CCD camera (Nikon, Tokyo, Japan) was analyzed using a computer equipped with a Komet 5.0 comet image analyzing system (Kinetic Imaging, Liverpool, UK). DNA damage caused by hydrogen peroxide in the leukocyte and inhibition of damage by the thyroid extract was calculated as 100% by measuring the DNA content in the tail portion which migrated from the nucleus and fell off to the tail portion. Two slides were made in each treatment, and DNA damage of each of 100 cells was measured. Each treatment was repeated twice.
그 결과, 발효한 쥐눈이콩의 경우 1 μg/mL 농도에서는 95.5%로 DNA 손상 억제 효과가 없었으나 나머지 농도에서는 68.6, 66.1, 44.4 %로 유의적 억제 효과가 나타났으며, 발효한 쥐눈이콩과 소금을 이용하여 만든 시료 B는 각 농도에서 71.3, 62.5, 53.0, 40.0 %, 죽염을 이용한 C는 83.9, 69.4, 52.4, 48.5% 그리고 죽염, 유근피, 밭마늘, 유황오리를 첨가하여 만든 시료 D에서는 76.4, 72.7, 55.8, 53.2%로 모든 농도에서 DNA 손상 억제 효과를 가지는 것으로 나타났다(도 9).
As a result, in the case of soybean fermented, the inhibition effect of DNA damage was not detected at 95.5% at 1 μg / mL concentration but 68.6, 66.1 and 44.4% at the other concentrations, respectively. , 76.4, 52.4, and 48.5%, respectively, for C with Bamboo salt, and 71.4, 62.5, 53.0, and 40.0% with B, respectively. In the case of Sample D, which was made by adding bamboo salt, , 72.7, 55.8, and 53.2%, respectively, indicating that they inhibit DNA damage at all concentrations (FIG. 9).
<< 실시예Example 5> 죽염과 5> Bamboo salt 쥐눈이콩A little bean 발효에 의해 생성된 발효조성물의 피로회복 효능 검증 Verification of fatigue recovery effect of fermentation composition produced by fermentation
<5-1> 실험동물의 준비 및 사육<5-1> Preparation and breeding of experimental animals
6주령 SD rat을 이용하여 1주일 적응 훈련을 한 후 본 실험에 앞서 물에 적응하게 하기 위하여 10분간 30-33℃의 수온에서 수영 적응 운동을 실시하였다. 본 실험에서는 일주일에 5회(20분/1회) 실시하여 2주간 사육하였다. 물의 온도는 30 ℃를 유지하도록 하였으며 모든 군의 실험조건은 동일하게 하기 위해 운동은 일정한 시간 실시하였다.Six - week old SD rats were used for one - week adaptive training. To adapt to water, swimming adaptation exercise was performed at 30-33 ℃ for 10 minutes. In this experiment, five times a week (20 minutes / once) was carried out and the animals were bred for 2 weeks. The temperature of water was maintained at 30 ℃ and the exercise was carried out for a certain period of time in order to make the experimental conditions of all groups the same.
양성 대조군, 음성 대조군(운동군+생리식염수), 발효조성물 투여군(운동+저농도 발효조성물, 운동+고농도 발효조성물) 별로 나누어 각각 실험 식이를 2주 동안 제공하였으며, 해부 당일 20분간 운동을 시킨 상태에서 동물을 희생시켜 혈액과 간을 수집하여 분석에 사용하였다.The experimental diets were divided into two groups according to the control group, the negative control group (exercise group + physiological saline), the fermentation composition administration group (exercise + low concentration fermentation composition, exercise + high concentration fermentation composition) Animals were sacrificed and blood and liver were collected and used for analysis.
1)NC: 음성 대조군, PC: 운동으로 유도된 피로, 0.5%: 운동으로 유도된 피로 + 0.5% 1) NC: negative control group, PC: exercise induced fatigue, 0.5%: exercise induced fatigue + 0.5%
발효된 쥐눈이콩, 죽염, 유근피, 밭마늘 및 유황오리의 발효조성물(샘플), 5%: 운동으로 유도된 피로 + 5% 샘플.Fermented composition (sample) of fermented peanut, bamboo salt, rhizome, field garlic and sulfur duck, 5%: exercise induced fatigue + 5% sample.
2)AIN 93 비타민 혼합물(vitamin mixture)은 다음을 포함한다(혼합물 중 g/kg 내): 티아민(thiamine) HCl 0.6; 리보플라빈(riboflavin) 0.6; 피리독신(pyridoxine) HCl 0.7; 니아신(niacin) 3) d-칼슘 판토텐산염(d-calcium pantothenate) 1.6; 엽산(folic acid) 0.2; d-비오틴(d-biotin) 0.02; 시아노코발라민(cyanocobalamin)(비타민 B12) 2.5; 건조 비타민 A 팔미테이트(dry vitamin A palmitate)(500,000 U/d) 0.8; 건조 비타민 E 아세테이트(dry vitamin E acetate)(500 U/d) 15; 비타민 D3 배산(vitamin D3 trituration)(400,000 U/g) 0.25; 비타민 K1 0.075 메나디온 아황산수소나트륨 복합체(menadione sodium bisulfite complex) 0.15; 잘게 분말화된 설탕(sucrose finely powdered) 981.08. 2) AIN 93 vitamin mixtures include (in g / kg of mixture): thiamine HCl 0.6; Riboflavin 0.6; Pyridoxine HCl 0.7; Niacin 3) d-calcium pantothenate 1.6; Folic acid 0.2; 0.0 > d-biotin < / RTI >0.02; Cyanocobalamin (vitamin B 12 ) 2.5; Dry vitamin A palmitate (500,000 U / d) 0.8; Dry vitamin E acetate (500 U / d) 15; Vitamin D 3 Baesan (vitamin D 3 trituration) (400,000 U / g) 0.25; Vitamin K1 0.075 Menadione sodium bisulfite complex 0.15; Sucrose finely powdered 981.08.
3)AIN 93 미네랄 혼합물(mineral mixture)은 다음을 포함한다(혼합물 중 g/kg 내): 인산칼슘(calcium phosphate), 2염기성(dibasic) 500; 염화나트륨(sodium chloride) 74; 구연산칼륨(potassium citrate), 일수화물(monohydrate) 220; 황산칼륨(potassium sulfate) 52; 산화마그네슘(magnesium oxide) 24; 탄산망간(manganous carbonate)(43-48% Mn) 3.5; 구연산철(ferric citrate)(16-17% Fe) 6; 탄산아연(zinc carbonate)(70% ZnO) 1.6; 탄산제2동(cupric carbonate)(53-55% Cu) 0.3; 요오드염(potassium iodate) 0.01; 아셀렌산나트륨(sodium selenite) 0.01; 황산크롬칼륨(chromium potassium sulfate) 0.55; 잘게 분말화된 설탕(sucrose, finely powdered) 118.03.
3) AIN 93 The mineral mixture includes the following (in g / kg of mixture): calcium phosphate, dibasic 500; Sodium chloride 74; Potassium citrate, monohydrate 220; Potassium sulfate 52; Magnesium oxide 24; Manganous carbonate (43-48% Mn) 3.5; Ferric citrate (16-17% Fe) 6; Zinc carbonate (70% ZnO) 1.6; Cupric carbonate (53-55% Cu) 0.3; Potassium iodate 0.01; Sodium selenite 0.01; Chromium potassium sulfate 0.55; Sucrose (finely powdered) 118.03.
실험동물을 희생시키기 전 12시간 동안 금식을 시킨 후, 드라이아이스에서 발생하는 CO2를 이용하여 마취하였으며 복부 대동맥으로부터 혈액을 채취하고 헤파린으로 응고를 방지하였다. 희생 즉시 젖산을 분석하고 난 나머지 혈액을 3000 rpm에서 30분간 원심분리 하여 혈장과 적혈구를 분리하여 분석시까지 -70℃에 냉동 보관하였다. 실험동물의 장기는 적출하여 생리식염수에 세척한 후, 흡수지로 물기를 제거하고 무게를 측정한 후 간은 액체 질소로 급속 냉동시킨 후 분석시까지 -70℃에 냉동 보관하였다.
The animals were fasted for 12 hours before sacrifice, and then anesthetized with CO 2 from dry ice. Blood was collected from the abdominal aorta and coagulated with heparin. At the time of sacrifice, the remaining blood was analyzed by centrifugation at 3000 rpm for 30 minutes. Plasma and erythrocytes were separated from each other and stored frozen at -70 ° C until analysis. The organs of the experimental animals were extracted and washed with physiological saline, the water was removed from the absorbent paper and the weight was measured. The liver was rapidly frozen in liquid nitrogen and stored at -70 ° C until analysis.
<5-2> 실험동물의 체중증가량, <5-2> Weight gain, 식이섭취량Dietary intake 및 식이 효율 확인 And checking diet efficiency
실험기간 중 체중증가량과 식이섭취량을 측정한 결과. 각 그룹간의 유의적 차이는 없는 것으로 나타났다(표 7). Weight gain and dietary intake during the experimental period. There was no significant difference between the groups (Table 7).
1)NC: 음성 대조군, PC: 운동으로 유도된 피로, 0.5%: 운동으로 유도된 피로 + 0.5% 1) NC: negative control group, PC: exercise induced fatigue, 0.5%: exercise induced fatigue + 0.5%
발효된 쥐눈이콩, 죽염, 유근피, 밭마늘 및 유황오리의 발효조성물(샘플), 5%: 운동으로 유도된 피로 + 5% 샘플.Fermented composition (sample) of fermented peanut, bamboo salt, rhizome, field garlic and sulfur duck, 5%: exercise induced fatigue + 5% sample.
2)FER: 식이효율(Food efficiency rate). 2) FER: Food efficiency rate.
3)평균 ± 표준편차(Mean ± SE). 3) Mean ± SE (Mean ± SE).
4)ns: 유의적이지 않음. 4) ns: Not significant.
5)칼럼 내에 다양한 첨자를 가진 수치는 p<0.05에서 유의적임.
5) Numbers with various subscripts in the column are significant at p <0.05.
<5-3> 실험동물의 장기무게 확인<5-3> Identification of organ weights of experimental animals
실험기간 중 장기무게를 측정한 결과, 간, 신장 및 심장의 무게에서는 그룹간 특이사항을 확인할 수 없었으며, 비장무게에서는 NC에 비해 PC에서 유의적 감소결과를 보였다. 그러나 PC와 저농도와 고농도 사리장 섭취군 사이에서는 유의적 차이가 없는 것으로 나타났다(표 8). During the experimental period, weights of liver, kidney, and heart were not different between groups, but PC showed a significant decrease in spleen weight compared to NC. However, there was no significant difference between PC and low-concentration and high-concentration sari-intake groups (Table 8).
1)NC: 음성 대조군, PC: 운동으로 유도된 피로, 0.5%: 운동으로 유도된 피로 + 0.5% 1) NC: negative control group, PC: exercise induced fatigue, 0.5%: exercise induced fatigue + 0.5%
발효된 쥐눈이콩, 죽염, 유근피, 밭마늘 및 유황오리의 발효조성물(샘플), 5%: 운동으로 유도된 피로 + 5% 샘플.Fermented composition (sample) of fermented peanut, bamboo salt, rhizome, field garlic and sulfur duck, 5%: exercise induced fatigue + 5% sample.
2)평균 ± 표준편차(Mean ± SE). 2) Mean ± SE (Mean ± SE).
3)ns: 유의적이지 않음. 3) ns: Not significant.
4)칼럼 내에 다양한 첨자를 가진 수치는 p<0.05에서 유의적임.
4) Numbers with various subscripts in the column are significant at p <0.05.
<5-4> 실험동물의 혈중 항산화 활성 및 과산화지질 측정<5-4> Antioxidant activity and lipid peroxidation in blood of experimental animals
혈장 내 총항산화력(Total radical trapping antioxidant potential, TRAP)은 다음과 같이 측정하였다. 구체적으로, ABTS(2,2-azinobis(3-ethylbenzothiazo-line 6-sulfonate), 150 mM)와 메트미오글로빈(metmyoglobin)(25 mM)을 H2O2(75 mM)로 활성화시킴으로써 생성된 페릴 미오글로빈 라디칼 종(ferryl myoglobin radical species)과의 상호 작용에 의해 형성된 ABTS 라디칼 양이온(radical cation)의 흡수(absorbance)의 억제 정도를 측정하는 방법이다. 이는 시료(0.84% 혈장)에 들어 있는 항산화 능력(antioxidant capacity)에 비례하게 된다. 시료를 8분 동안 30℃에서 배양한 후 UV/VIS spectrophotometer로 740 nm의 파장에서 흡광도(absorbance)를 측정하였다. 혈장의 TRAP 농도는 trolox의 검량선(calibration curve)을 이용하여 계산하며 TEAC(Trolox equivalent antioxidant capacity, mM)으로 표현하였다.The total antioxidant potential (TRAP) was measured as follows. Specifically, peryl myoglobin produced by activating ABTS (2,2-azinobis (3-ethylbenzothiazo-line 6-sulfonate), 150 mM) and metmyoglobin (25 mM) with H 2 O 2 Is a method for measuring the degree of inhibition of absorption of an ABTS radical cation formed by interaction with a radical species (ferryl myoglobin radical species). This is proportional to the antioxidant capacity contained in the sample (0.84% plasma). The samples were incubated for 8 min at 30 ° C. and then absorbance was measured at a wavelength of 740 nm using a UV / VIS spectrophotometer. Plasma TRAP concentrations were calculated using the calibration curve of trolox and expressed as TEAC (Trolox equivalent antioxidant capacity, mM).
혈장 내 과산화 지질 농도는 다음과 같이 측정하였다. 구체적으로, 혈장을 0.064 M 시트르산삼나트륨(trisodium citrate)과 헤파린(heparin)으로 처리하여 원심분리한 뒤 LDL-콜레스테롤(cholesterol)을 분리하였다. LDL-콜레스테롤로부터 지질을 추출하기 위해 클로로포름-메탄올(chloroform-methanol)를 처리한 뒤 시클로헥산(cyclohexane)으로 녹여 234 nm에서 그 흡광도를 측정하였다.The plasma lipid peroxide concentration was measured as follows. Specifically, plasma was treated with 0.064 M trisodium citrate and heparin, centrifuged, and LDL-cholesterol was isolated. To extract lipids from LDL-cholesterol, chloroform-methanol (chloroform-methanol) was treated with cyclohexane and the absorbance was measured at 234 nm.
그 결과, TRAP의 경우, NC에 비해 PC에서 유의적으로 낮은 활성을 보였으며 이는 저농도 발효조성물을 섭취함으로써 NC의 수준으로 향상되는 것을 알 수 있었다. CD의 경우, NC에 비해 PC에서 높은 활성을 보였으며 이는 고농도 발효조성물을 섭취함으로써 감소시키는 것을 알 수 있었다(표 9).As a result, TRAP showed a significantly lower activity in PC than NC, and it was found to be improved to the level of NC by ingesting the low concentration fermentation composition. CD showed higher activity in PC than in NC, which was decreased by ingesting high-concentration fermentation composition (Table 9).
1)NC: 음성 대조군, PC: 운동으로 유도된 피로, 0.5%: 운동으로 유도된 피로 + 0.5% 1) NC: negative control group, PC: exercise induced fatigue, 0.5%: exercise induced fatigue + 0.5%
발효된 쥐눈이콩, 죽염, 유근피, 밭마늘 및 유황오리의 발효조성물(샘플), 5%: 운동으로 유도된 피로 + 5% 샘플.Fermented composition (sample) of fermented peanut, bamboo salt, rhizome, field garlic and sulfur duck, 5%: exercise induced fatigue + 5% sample.
2)평균 ± 표준편차(Mean ± SE). 2) Mean ± SE (Mean ± SE).
3)칼럼 내에 다양한 첨자를 가진 수치는 p<0.05에서 유의적임. 3) Numbers with various subscripts in the column are significant at p <0.05.
4)ns: 유의적이지 않음.
4) ns: Not significant.
<5-5> 실험동물의 혈중 항산화 효소 분석<5-5> Analysis of antioxidant enzyme in blood of experimental animals
카탈라아제(Catalase) 효소 활성 측정의 원리는 과산화수소(hydrogen peroxide)가 물과 산소로 분해되는 반응을 촉매하여 과산화수소의 감소량을 측정하게 되며, 반응속도는 과산화수소의 농도와 비례한다. 과산화수소의 농도가 0.1 M이상이면 카탈라아제에 의한 반응이 억제되므로 약 0.01 M의 적은 농도를 사용해야 한다. 반응이 잘 이뤄지게 하기 위해서는 반응 시작 후 늦어도 30초 후에 적혈구에 50 mM 인산 완충용액(phosphate buffer)(pH 7) 및 과산화수소를 첨가한 후 과산화수소의 감소량을 240 nm에서 30초간 측정하였다.The principle of catalase enzyme activity is catalyzed by the decomposition of hydrogen peroxide into water and oxygen to measure the amount of hydrogen peroxide reduction. The reaction rate is proportional to the concentration of hydrogen peroxide. If the concentration of hydrogen peroxide is more than 0.1 M, the reaction by catalase is inhibited. Therefore, a small concentration of about 0.01 M should be used. For the reaction to proceed well, 50 mM phosphate buffer (pH 7) and hydrogen peroxide were added to the red blood cells at the latest 30 seconds after the start of the reaction, and the amount of hydrogen peroxide reduction was measured at 240 nm for 30 seconds.
그 결과, 카탈라아제의 활성은 NC에 비해 PC에서 유의적으로 감소하였고, 저농도군에서는 증가하는 경향은 보였다(표 10).As a result, catalase activity was significantly decreased in PC compared with NC, and increased in low concentration group (Table 10).
1)NC: 음성 대조군, PC: 운동으로 유도된 피로, 0.5%: 운동으로 유도된 피로 + 0.5% 1) NC: negative control group, PC: exercise induced fatigue, 0.5%: exercise induced fatigue + 0.5%
발효된 쥐눈이콩, 죽염, 유근피, 밭마늘 및 유황오리의 발효조성물(샘플), 5%: 운동으로 유도된 피로 + 5% 샘플.Fermented composition (sample) of fermented peanut, bamboo salt, rhizome, field garlic and sulfur duck, 5%: exercise induced fatigue + 5% sample.
2)평균 ± 표준편차(Mean ± SE). 2) Mean ± SE (Mean ± SE).
3)칼럼 내에 다양한 첨자를 가진 수치는 p<0.05에서 유의적임. 3) Numbers with various subscripts in the column are significant at p <0.05.
4)ns: 유의적이지 않음.
4) ns: Not significant.
<5-6> 실험동물의 백혈구 ≪ 5-6 > DNADNA 손상 확인 Check for damage
전혈 20 μL를 채취하여 75 μL의 0.7% 0.5% 저융해 아가로즈 겔(low melting agarose gel, LMA)과 섞은 후, 0.5% 정상 융해 아가로즈(normal melting agarose, NMA)가 전코팅(precoating)된 fully frosted slide 위로 전혈과 LMA의 현탁액이 골고루 분산되게 한 후 커버 글래스(cover glass)로 덮어 4℃ 냉장고에 보관하였다. Gel이 굳으면 커버 글래를 벗기고 그 위에 다시 0.7% LMA 용액 75 μL로 한 겹 더 덮었다. 세포 용해(Cell lysis)를 위해 미리 준비해 둔 차가운 alkali lysis buffer(2.5M NaCl, 100 mM EDTA, 10 mM tris)에 사용 직전에 1% Triton X-100을 섞은 후 슬라이드(slide)를 담가 저온, 암실에서 1시간 동안 침지시켜 DNA의 이중가닥(double strand)을 풀어주었다. 용해(Lysis)가 끝난 슬라이드를 존기영동 탱크(electrophoresis tank)에 배열하고 4℃의 차가운 완충용액(buffer)(300mM NaOH, 10mM Na2EDTA)를 채워 혈액은 20분간 unwinding 시킨 후 25V/300±3mA의 전압을 걸어 20분간 전기영동을 실시하였다. 전기영동이 끝난 후 0.4M Tris 완충용액(pH 7.4)으로 충분히 세척하고 20 μL/mL 농도의 브롬화 에디튬(ethidium bromide)으로 핵을 염색하여 형광 현미경으로 관찰하고 CCD 카메라를 통해 보내진 각각의 세포핵 이미지는 코멧 이미지 분석 시스템(comet image analyzing system)이 설치된 컴퓨터로 분석하였다. 백혈구 및 H2O2에 의한 백혈구의 DNA 손상이 지속적인 운동과 발효조성물을 섭취하였을 때 어떠한 영향을 미치는지 확인하였다.20 μL of whole blood was collected and mixed with 75 μL of 0.7% 0.5% low melting agarose gel (LMA), and then 0.5% normal melting agarose (NMA) was precoated A fully frosted slide over the whole blood and LMA suspension was spread over the cover glass and then stored in a refrigerator at 4 ° C. When the gel was hardened, the cover gum was peeled off and another layer was covered with 75 μL of a 0.7% LMA solution. Add 1% Triton X-100 immediately before use to cold lysis buffer (2.5M NaCl, 100 mM EDTA, 10 mM tris) prepared beforehand for cell lysis. For 1 hour to release the double strand of DNA. The lysed slides were placed in an electrophoresis tank and filled with cold buffer (300 mM NaOH, 10 mM Na2EDTA) at 4 ° C. The blood was unwound for 20 minutes and then applied with a voltage of 25 V / 300 ± 3 mA And electrophoresis was carried out for 20 minutes. After electrophoresis, the cells were washed thoroughly with 0.4 M Tris buffer (pH 7.4), stained with ethidium bromide at a concentration of 20 μL / mL, observed with a fluorescence microscope, Was analyzed with a computer equipped with a comet image analyzing system. The effect of leukocyte and H 2 O 2 -induced leukocyte DNA damage on continuous exercise and ingestion of the fermentation composition was examined.
그 결과, 백혈구의 DNA 손상 정도를 나타내는 tail DNA, tail moment 및 tail length에서 NC에 비해 PC에서 일부 증가하였고, 저농도군 및 고농도군에서 일부 감소하는 경향은 보였다(표 11).As a result, tail DNA, tail torque, and tail length indicating the degree of DNA damage of leukocytes were partially increased in PC compared to NC, and a tendency to decrease in low and high concentration groups was shown (Table 11).
1)NC: 음성 대조군, PC: 운동으로 유도된 피로, 0.5%: 운동으로 유도된 피로 + 0.5% 1) NC: negative control group, PC: exercise induced fatigue, 0.5%: exercise induced fatigue + 0.5%
발효된 쥐눈이콩, 죽염, 유근피, 밭마늘 및 유황오리의 발효조성물(샘플), 5%: 운동으로 유도된 피로 + 5% 샘플.Fermented composition (sample) of fermented peanut, bamboo salt, rhizome, field garlic and sulfur duck, 5%: exercise induced fatigue + 5% sample.
2)평균 ± 표준편차(Mean ± SE). 2) Mean ± SE (Mean ± SE).
3)ns: 유의적이지 않음.
3) ns: Not significant.
<< 실시예Example 6> 죽염과 6> Bamboo salt and 쥐눈이콩A little bean 발효에 의해 생성된 발효조성물의 숙취해소 효능 검증 Verification of hangover elimination effect of fermented composition produced by fermentation
<6-1> 실험동물의 준비 및 사육<6-1> Preparation and breeding of experimental animals
6주령의 수컷 Sprague-Dawley(SD)를 2 주일간 적응시킨 후, 실험 동물군을 4 그룹(정상대조군, 알코올 섭취군, 알코올+저농도 발효조성물 섭취군, 알코올+고농도 발효조성물 섭취군)으로 각 군별로 나누어 각각 실험 식이를 5주 동안 제공하였다. 실험 식이는 에탄올에 함유된 칼로리를 제외한 양을 섭취시키며 총열량의 25%를 에탄올로 공급하였다. 에탄올 공급은 5, 10, 15 20, 25%로 점진적으로 증가하여 충분한 적응을 할 수 있도록 하였다. 실험식이 제공 후 5주 후 동물을 희생시켜 혈액과 간을 수집하여 분석에 사용하였다Six weeks old male Sprague-Dawley (SD) was adapted for 2 weeks. The experimental animals were divided into 4 groups (normal control, alcohol consumption group, alcohol + low concentration fermentation composition intake group, alcohol + high concentration fermentation composition intake group) The experimental diet was given for 5 weeks. The experimental diet consumed an amount of calories not contained in ethanol and 25% of the total calories was fed into ethanol. The ethanol supply gradually increased to 5, 10, 15, 20, and 25%, so that sufficient adaptation was made. Five weeks after the empirical formula was given, animals were sacrificed and blood and liver were collected and used for analysis
1)NC: 음성 대조군(알코올을 공급하지 않음), PC: 25% 알코올 공급, 0.5%: 25% 알코올 공급 + 0.5% 샘플, 5%: 25% 알코올 공급 + 5% 샘플.PC: 25% alcohol supply, 0.5%: 25% alcohol supply + 0.5% sample, 5%: 25% alcohol supply + 5% sample , NC: negative control (without alcohol)
2)AIN 93 비타민 혼합물(vitamin mixture)은 다음을 포함한다(혼합물 중 g/kg 내): 티아민(thiamine) HCl 0.6; 리보플라빈(riboflavin) 0.6; 피리독신(pyridoxine) HCl 0.7; 니아신(niacin) 3) d-칼슘 판토텐산염(d-calcium pantothenate) 1.6; 엽산(folic acid) 0.2; d-비오틴(d-biotin) 0.02; 시아노코발라민(cyanocobalamin)(비타민 B12) 2.5; 건조 비타민 A 팔미테이트(dry vitamin A palmitate)(500,000 U/d) 0.8; 건조 비타민 E 아세테이트(dry vitamin E acetate)(500 U/d) 15; 비타민 D3 배산(vitamin D3 trituration)(400,000 U/g) 0.25; 비타민 K1 0.075 메나디온 아황산수소나트륨 복합체(menadione sodium bisulfite complex) 0.15; 잘게 분말화된 설탕(sucrose finely powdered) 981.08. 2) AIN 93 vitamin mixtures include (in g / kg of mixture): thiamine HCl 0.6; Riboflavin 0.6; Pyridoxine HCl 0.7; Niacin 3) d-calcium pantothenate 1.6; Folic acid 0.2; 0.0 > d-biotin < / RTI >0.02; Cyanocobalamin (vitamin B 12 ) 2.5; Dry vitamin A palmitate (500,000 U / d) 0.8; Dry vitamin E acetate (500 U / d) 15; Vitamin D 3 Baesan (vitamin D 3 trituration) (400,000 U / g) 0.25; Vitamin K1 0.075 Menadione sodium bisulfite complex 0.15; Sucrose finely powdered 981.08.
3)AIN 93 미네랄 혼합물(mineral mixture)은 다음을 포함한다(혼합물 중 g/kg 내): 인산칼슘(calcium phosphate), 2염기성(dibasic) 500; 염화나트륨(sodium chloride) 74; 구연산칼륨(potassium citrate), 일수화물(monohydrate) 220; 황산칼륨(potassium sulfate) 52; 산화마그네슘(magnesium oxide) 24; 탄산망간(manganous carbonate)(43-48% Mn) 3.5; 구연산철(ferric citrate)(16-17% Fe) 6; 탄산아연(zinc carbonate)(70% ZnO) 1.6; 탄산제2동(cupric carbonate)(53-55% Cu) 0.3; 요오드염(potassium iodate) 0.01; 아셀렌산나트륨(sodium selenite) 0.01; 황산크롬칼륨(chromium potassium sulfate) 0.55; 잘게 분말화된 설탕(sucrose, finely powdered) 118.03.
3) AIN 93 The mineral mixture includes the following (in g / kg of mixture): calcium phosphate, dibasic 500; Sodium chloride 74; Potassium citrate, monohydrate 220; Potassium sulfate 52; Magnesium oxide 24; Manganous carbonate (43-48% Mn) 3.5; Ferric citrate (16-17% Fe) 6; Zinc carbonate (70% ZnO) 1.6; Cupric carbonate (53-55% Cu) 0.3; Potassium iodate 0.01; Sodium selenite 0.01; Chromium potassium sulfate 0.55; Sucrose (finely powdered) 118.03.
실험동물을 희생시키기 전 12시간 동안 금식을 시킨 후 , 드라이아이스에서 발생하는 CO2를 이용하여 마취하여 복부 대동맥으로부터 혈액을 채취하고 헤파린으로 응고를 방지하였다. 코멧 분석(Comet assay)을 실시한 나머지 혈액을 3000 rpm에서 30분간 원심분리 하여 혈장과 적혈구를 분리하여 분석 시까지 -70℃에 냉동 보관하였다. 실험동물의 장기는 적출하여 생리식염수에 세척한 후, 흡수지로 물기를 제거하고 무게를 측정한 후 간은 0.5 g 적출하여 코멧 분석을 위해 HBSS buffer에 담가 즉시 사용하였으며, 나머지는 액체 질소로 급속 냉동시킨 후 분석 시까지 -70℃에 냉동 보관하였다.
The animals were fasted for 12 hours before sacrifice and blood was drawn from the abdominal aorta by anesthesia using CO 2 generated from dry ice to prevent clotting with heparin. After the Comet assay, the blood was centrifuged at 3000 rpm for 30 minutes, and plasma and erythrocytes were separated and stored at -70 ° C until analysis. After removing the water from the absorbent paper and measuring the weight, 0.5 g of the liver was extracted and immediately used by immersing it in HBSS buffer for analysis of comet. The rest of the animals were immediately frozen with liquid nitrogen And stored frozen at -70 ° C until analysis.
<6-2> 실험동물의 체중증가량, <6-2> Weight gain, 식이섭취량Dietary intake 및 식이 효율 확인 And checking diet efficiency
실험기간 중 체중증가량과 식이섭취량을 측정한 결과. 각 그룹간의 유의적 차이는 없는 것으로 나타났다(표 13). Weight gain and dietary intake during the experimental period. There was no significant difference between the groups (Table 13).
1)NC: 음성 대조군(알코올을 공급하지 않음), PC: 25% 알코올 공급, 0.5%: 25% 알코올 공급 + 0.5% 샘플, 5%: 25% 알코올 공급 + 5% 샘플.PC: 25% alcohol supply, 0.5%: 25% alcohol supply + 0.5% sample, 5%: 25% alcohol supply + 5% sample , NC: negative control (without alcohol)
2)FER: 식이효율(Food efficiency rate). 2) FER: Food efficiency rate.
3)평균 ± 표준편차(Mean ± SE). 3) Mean ± SE (Mean ± SE).
4)칼럼 내에 다양한 첨자를 가진 수치는 p<0.05에서 유의적임.
4) Numbers with various subscripts in the column are significant at p <0.05.
<6-3> 실험동물의 장기무게 확인<6-3> Identification of organ weights of experimental animals
실험기간 중 장기무게를 측정한 결과, 간, 신장, 심장 및 비장의 무게에 영향을 미치지 않는 것으로 나타났다(표 14). Long-term weight measurements during the experiment did not affect liver, kidney, heart, and spleen weights (Table 14).
1)NC: 음성 대조군(알코올을 공급하지 않음), PC: 25% 알코올 공급, 0.5%: 25% 알코올 공급 + 0.5% 샘플, 5%: 25% 알코올 공급 + 5% 샘플.PC: 25% alcohol supply, 0.5%: 25% alcohol supply + 0.5% sample, 5%: 25% alcohol supply + 5% sample , NC: negative control (without alcohol)
2)평균 ± 표준편차(Mean ± SE). 2) Mean ± SE (Mean ± SE).
3)ns: 유의적이지 않음.
3) ns: Not significant.
<6-4> 실험동물의 간 손상 지표 확인<6-4> Identification of Liver Damage Index in Laboratory Animals
혈중 AST(aspartate aminotransferase)와 ALT(alanine aminotransferase)는 kit(Asan Pharmaceutical, Korea)를 사용하여 기질과 효소반응을 이용한 비색법에 의해 제조된 kit(Asan Pharmaceutical, Korea)를 이용하여 측정하였다.Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured using a kit (Asan Pharmaceutical, Korea) which was prepared by colorimetric assay using substrate and enzyme reaction using kit (Asan Pharmaceutical, Korea).
그 결과, AST 및 ALT 두 효소 모두 NC군에 비해 PC군에서 유의적으로 높게 나타나 5주간의 알코올 섭취가 간 손상에 영향을 미친 것으로 확인되었다. 또한 저농도군에서는 PC에 비해 효소의 활성이 감소하는 것으로 나타났다(표 15).As a result, both AST and ALT enzymes were significantly higher in PC group than NC group, and it was confirmed that alcohol consumption for 5 weeks affected liver damage. In the low concentration group, the activity of the enzyme was decreased compared to PC (Table 15).
1)NC: 음성 대조군(알코올을 공급하지 않음), PC: 25% 알코올 공급, 0.5%: 25% 알코올 공급 + 0.5% 샘플, 5%: 25% 알코올 공급 + 5% 샘플.PC: 25% alcohol supply, 0.5%: 25% alcohol supply + 0.5% sample, 5%: 25% alcohol supply + 5% sample , NC: negative control (without alcohol)
2)평균 ± 표준편차(Mean ± SE). 2) Mean ± SE (Mean ± SE).
3)칼럼 내에 다양한 첨자를 가진 수치는 p<0.05에서 유의적임. 3) Numbers with various subscripts in the column are significant at p <0.05.
4)ns: 유의적이지 않음.
4) ns: Not significant.
<6-5> 실험동물의 적혈구 항산화효소 활성 확인<6-5> Identification of erythrocyte antioxidant enzyme activity in experimental animals
글루타티온고산화효소(Glutathione peroxidase, GSH-Px)는 과산화물(t-butylhydroperoxide)에 의해 글루타티온(glutathione)이 산화되는 반응을 촉매 한다. 이때 산화된 글루타티온은 글루타티온 리덕타아제(glutathione reductase)와 NADPH의 존재 하에 다시 글루타티온으로 환원되고 NADPH는 NADP로 산화된다. 이러한 원리로 용혈된 적혈구에 글루타티온, 글루타티온 리덕타아제, NADPH를 첨가하고 37℃, 10분간 방치한 뒤 t-부틸하이드로퍼옥시드(t-butylhydroperoxide)를 넣어 반응시켰으며 이때 감소된 NADPH 농도를 340 nm에서 90초간 측정함으로써 GSH-Px(U/g HB)의 항산화 정도를 측정하였다.Glutathione peroxidase (GSH-Px) catalyzes the oxidation of glutathione by t-butylhydroperoxide. At this time, the oxidized glutathione is reduced again to glutathione in the presence of glutathione reductase and NADPH, and NADPH is oxidized to NADP. Glutathione, glutathione reductase and NADPH were added to hemolyzed red blood cells, and the mixture was allowed to stand at 37 ° C for 10 minutes and then reacted with t-butylhydroperoxide. The reduced NADPH concentration was 340 nm for 90 seconds to measure the degree of antioxidation of GSH-Px (U / g HB).
그 결과, GSH-Px 활성의 경우, NC에 비해 PC에서 유의적으로 활성이 낮아지는 결과를 보였으며, 저농도군 및 고농도군의 활성이 모두 증가하는 것을 알 수 있었다(표 16). As a result, GSH-Px activity was significantly lowered in PC than in NC, and activity of both low and high concentration groups was increased (Table 16).
1)NC: 음성 대조군(알코올을 공급하지 않음), PC: 25% 알코올 공급, 0.5%: 25% 알코올 공급 + 0.5% 샘플, 5%: 25% 알코올 공급 + 5% 샘플.PC: 25% alcohol supply, 0.5%: 25% alcohol supply + 0.5% sample, 5%: 25% alcohol supply + 5% sample , NC: negative control (without alcohol)
2)평균 ± 표준편차(Mean ± SE). 2) Mean ± SE (Mean ± SE).
3)칼럼 내에 다양한 첨자를 가진 수치는 p<0.05에서 유의적임.
3) Numbers with various subscripts in the column are significant at p <0.05.
<< 제조예Manufacturing example 1> 약학적 제제의 제조 1> Preparation of pharmaceutical preparations
<1-1> <1-1> 산제의Sanje 제조 Produce
본 발명의 조성물 2 g2 g of the composition of the present invention
유당 1 gLactose 1 g
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above components were mixed and packed in airtight bags to prepare powders.
<1-2> 정제의 제조<1-2> Preparation of tablets
본 발명의 조성물 100 mg100 mg of the composition of the present invention
옥수수전분 100 mg
유 당 100 mg100 mg of milk
스테아린산 마그네 2 mgMagnesium stearate 2 mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
<1-3> 캡슐제의 제조≪ 1-3 > Preparation of capsules
본 발명의 조성물 100 mg100 mg of the composition of the present invention
옥수수전분 100 mg
유 당 100 mg100 mg of milk
스테아린산 마그네슘 2 mgMagnesium stearate 2 mg
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
<1-4> 환의 제조≪ 1-4 >
본 발명의 조성물 1 g1 g of the composition of the present invention
유당 1.5 gLactose 1.5 g
글리세린 1 gGlycerin 1 g
자일리톨 0.5 g0.5 g of xylitol
상기의 성분을 혼합한 후, 통상의 방법에 따라 1환 당 4 g이 되도록 제조하였다.
After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.
<1-5> 과립의 제조<1-5> Preparation of granules
본 발명의 조성물 150 mg150 mg of the composition of the present invention
대두추출물 50 mgSoybean extract 50 mg
포도당 200 mg
전분 600 mg
상기의 성분을 혼합한 후, 30% 에탄올 100 mg을 첨가하여 섭씨 60℃ 에서 건조하여 과립을 형성한 후 포에 충진하였다.
After mixing the above components, 100 mg of 30% ethanol was added and the mixture was dried at 60 ° C to form granules, which were filled in a capsule.
<< 제조예Manufacturing example 2> 건강식품의 제조 2> Manufacture of health food
<2-1> 밀가루 식품의 제조<2-1> Production of flour food
본 발명의 조성물 0.5 ~ 5.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하였다.
0.5-5.0 parts by weight of the composition of the present invention was added to wheat flour, and the mixture was used to prepare bread, cake, cookies, crackers and noodles.
<2-2> <2-2> 스프soup 및 육즙( And juicy ( graviesgravies )의 제조)
본 발명의 조성물 0.1 ~ 5.0 중량부를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.
0.1 to 5.0 parts by weight of the composition of the present invention was added to soups and gravies to prepare meat products for health promotion, soup of noodles and juices.
<2-3> 그라운드 <2-3> Ground 비프(ground beef)의Beef 제조 Produce
본 발명의 조성물 10 중량부를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.
10 parts by weight of the composition of the present invention was added to ground beef to prepare ground beef for health promotion.
<2-4> 유제품(<2-4> Dairy products ( dairydairy productsproducts )의 제조)
본 발명의 조성물 5 ~ 10 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
5-10 parts by weight of the composition of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
<2-5> <2-5> 선식의Solar 제조 Produce
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
본 발명의 조성물을 진공 농축기에서 감압농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The composition of the present invention was concentrated under reduced pressure in a vacuum concentrator, dried by spraying, and dried with a hot-air drier, and the resulting dried product was pulverized to a particle size of 60 mesh with a pulverizer to obtain a dried powder.
상기에서 제조한 곡물류, 종실류 및 본 발명의 조성물을 다음의 비율로 배합하여 제조하였다.The grains, seeds, and the composition of the present invention prepared above were blended in the following proportions.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
본 발명의 조성물(3 중량부),The composition of the present invention (3 parts by weight)
영지(0.5 중량부),(0.5 part by weight),
지황(0.5 중량부).
Rhubarb (0.5 parts by weight).
<< 제조예Manufacturing example 3> 3> 건강음료의Health drink 제조 Produce
<3-1> 건강 음료의 제조<3-1> Production of health drinks
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 본 발명의 조성물 5 g을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 제조하였다.
5 g of the composition of the present invention was homogeneously mixed with a sub ingredient such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75% It was packaged in small containers such as glass bottles and plastic bottles.
<3-2> 야채 주스의 제조<3-2> Preparation of vegetable juice
본 발명의 조성물 5 g을 토마토 또는 당근 주스 1,000 에 가하여 야채 주스를 제조하였다.
5 g of the composition of the present invention was added to 1,000 tomato or carrot juices to prepare vegetable juice.
<3-3> 과일 주스의 제조<3-3> Production of fruit juice
본 발명의 조성물 1 g을 사과 또는 포도 주스 1,000 에 가하여 과일 주스를 제조하였다.
1 g of the composition of the present invention was added to 1,000 apples or grape juices to prepare fruit juice.
Claims (14)
Rye beans ( Rhynchosia Nulubilis ), bamboo salt, rhizome , field garlic and sulfur duck.
The fermentation composition according to any one of claims 1 to 3, wherein the dry husk comprises soybean: bamboo salt: yuukee: field garlic: sulfur duck in a weight ratio of 1: 1: 0.5 to 1: 0.5 to 1: 0.5 to 1.
2. The fermentation composition according to claim 1, wherein the soybean bean is a fermented soybean fermented first.
The fermentation composition according to claim 1, wherein the bamboo salt is 9-fold bamboo salt.
2) 상기 단계 1)의 쥐눈이콩에 누룩을 접종한 후 발효시킨 다음 건조시키는 단계;
3) 상기 단계 2)의 건조된 쥐눈이콩에 죽염, 유근피, 밭마늘 및 유황오리를 혼합시키는 단계;
4) 상기 단계 3)의 혼합물을 1차 숙성시킨 후 여과한 다음 가열하는 단계;
5) 상기 단계 4)의 발효물을 2차 숙성시키는 단계를 포함하는,
쥐눈이콩, 죽염, 유근피, 밭마늘 및 유황오리를 포함하는 발효조성물의 제조방법.
1) washing and growing the bean sole and cooling;
2) Inoculating the yeast into the legs of the step 1), then fermenting the yeast, and then drying it;
3) mixing the bamboo shoots, yucci, field garlic, and sulfur ducks with dried legs of step 2);
4) first aging the mixture of step 3), filtering and then heating;
5) secondary aging the fermented product of step 4)
A method for producing a fermented composition comprising a legged bean, a bamboo salt, a rhizome, a field garlic, and a sulfur duck.
The fermented composition according to claim 5, wherein the fermentation of step 2) is performed at 32 to 38 ° C for 15 to 20 hours.
6. The method according to claim 5, wherein the drying in step 2) is performed at 30 to 40 DEG C for 12 to 15 hours.
[Claim 6] The method according to claim 5, wherein the yugi, field, and duck ducks of step 3) are extracted with hot water and then extracted with purified water.
6. The fermented composition according to claim 5, wherein the mixing of step 3) is carried out in a weight ratio of 1: 1: 1: 0.7: 0.8 in the ratio of bean, bamboo salt, .
The fermented composition according to claim 5, wherein the heating in step 4) is performed at 80 to 100 ° C for 30 minutes to 1 hour.
6. A pharmaceutical composition for chewing a fatigue containing the fermented composition according to any one of claims 1 to 4.
A pharmaceutical composition for hangover use containing the fermentation composition according to any one of claims 1 to 4.
A health food for eating a fatigue containing the fermented composition of any one of claims 1 to 4.
A health food for hangover habit containing the fermented composition according to any one of claims 1 to 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130149336A KR20150064521A (en) | 2013-12-03 | 2013-12-03 | Fermented composition comprising bamboo salt and rhynchosia nulubilis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130149336A KR20150064521A (en) | 2013-12-03 | 2013-12-03 | Fermented composition comprising bamboo salt and rhynchosia nulubilis |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20150064521A true KR20150064521A (en) | 2015-06-11 |
Family
ID=53503064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130149336A KR20150064521A (en) | 2013-12-03 | 2013-12-03 | Fermented composition comprising bamboo salt and rhynchosia nulubilis |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20150064521A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102023961B1 (en) * | 2019-07-15 | 2019-11-04 | 장현진 | Extract of Chicken Leg Using Fermented Soybean and The Method Thereof |
KR20200005065A (en) * | 2018-07-05 | 2020-01-15 | 인산죽염주식회사 | Functional food having growth inhibition of human colon cancer cell and method for manufacturing the same |
-
2013
- 2013-12-03 KR KR1020130149336A patent/KR20150064521A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200005065A (en) * | 2018-07-05 | 2020-01-15 | 인산죽염주식회사 | Functional food having growth inhibition of human colon cancer cell and method for manufacturing the same |
KR102023961B1 (en) * | 2019-07-15 | 2019-11-04 | 장현진 | Extract of Chicken Leg Using Fermented Soybean and The Method Thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070166320A1 (en) | Agent for preventing/ameliorating diabetes and functional food for preventing/ameliorating diabetes | |
KR20140103622A (en) | The method for manufacturing functional tea product made from onion skin, and the product made by the method | |
JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
Tamer et al. | Toxicological aspects of ingredients used in nonalcoholic beverages | |
KR20170078975A (en) | Bread and bread composition with antioxidative activity containing the rind of apples and blueberries | |
KR20200074985A (en) | High quality bamboo powder and its manufacturing method and use | |
KR101363111B1 (en) | Pharmaceutical composition containing paddy husk and barley husk extract as activeingredient | |
Srivastava et al. | Dynamic bioactive properties of nutritional superfood Moringa oleifera: A comprehensive review | |
KR101935500B1 (en) | Composition for Preventing and Treating Neurodegenerative Diseases Comprising germinated oats extract having high-content avenanthramides | |
KR100504351B1 (en) | Food composition for reducing alcoholic hangup containing plant extracts or powders | |
KR100855665B1 (en) | Kochujang for anti-cholesterol comprising persimmon fruit and extracts of herb medicine mixture and a preparation method thereof | |
KR20150064521A (en) | Fermented composition comprising bamboo salt and rhynchosia nulubilis | |
KR102002080B1 (en) | Method for producing glutinous rice cake using persimmon, grain and medicinal plant | |
KR102487459B1 (en) | Manufacturing method of health food having antioxidant activity containing fermented polygonum multiflorum complex extracts and the health food having antioxidant activity thereby | |
Akiode et al. | Nutrients, phytochemical composition and antioxidant analysis of selected agricultural wastes as potential livestock feed ingredients | |
KR101586053B1 (en) | method manufacturing Powder of Cudrania tricuspidata | |
KR101894491B1 (en) | A composition for improving memory or cognitive function comprising a aurantii fructus immaturus supercritical extract as an active ingredient | |
KR102087291B1 (en) | Aronia soymilk and manufacturing method thereof | |
KR102485676B1 (en) | A composition for improving, preventing and treating of obesity comprising Ulva pertusa Kjellman extracts | |
KR101845704B1 (en) | Composition comprising kynurenic acid for relieving hangover | |
Khojah et al. | Fortification of macaroni with pomegranate peels as dietary fiber and natural antioxidant for the treatment of obesity and high cholesterol in rats | |
KR101944333B1 (en) | Composition for Functional Manju Comprising Nurungji and Aronia & Method Using Thereof | |
Damayanti et al. | Nutritional contents and the utilization of Indonesian native starfruits: Averrhoa dolicocarpa and A. leucopetala | |
KR20180127574A (en) | Mixed food material powder comprising acetic acid fermentation powder and preparation method thereof | |
KR102299517B1 (en) | Method for producing functional grain tea comprising oat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |